Next Article in Journal
Minimally Invasive Total Versus Partial Thymectomy for Early-Stage Thymoma
Previous Article in Journal
Comparative Outcomes of Gross Total Resection vs. Subtotal Resection Plus Radiotherapy for Preventing Craniopharyngioma Recurrence: A Meta-Analysis of the Endoscopic Endonasal Approach
Previous Article in Special Issue
Prognostic Significance of Interim PET/CT in the First-Line Treatment of Follicular Lymphoma Patients, a Single-Center Experience
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 15
10.3390/cancers17152517
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma

by
Jahnavi Chaudhari
1,2 and
Nikesh N. Shah
3,*
1
Department of Internal Medicine, HCA Florida Oak Hill Hospital, Brooksville, FL 34613, USA
2
USF Health Morsani College of Medicine, Tampa, FL 33602, USA
3
Department of Malignant Hematology, Tampa General Hospital Cancer Institute, Tampa, FL 33629, USA
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(15), 2517; https://doi.org/10.3390/cancers17152517
Submission received: 26 June 2025 / Revised: 28 July 2025 / Accepted: 28 July 2025 / Published: 30 July 2025
(This article belongs to the Special Issue Advances in B-Cell Lymphoma: From Diagnostics to Cure)
Browse Figure
Versions Notes

Simple Summary

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with a significant relapse rate despite standard chemoimmunotherapy. This manuscript reviews emerging targeted therapy and immunotherapies, particularly for patients who are unable to receive chimeric antigen receptor T-cell (CAR-T) therapy due to rapid disease growth, medical comorbidities, distance from a CAR-T center, or socioeconomic barriers. Bispecific antibodies and antibody–drug conjugates have shown promising efficacy, especially when used in combination together or with chemotherapy. Ongoing studies are further evaluating their use in newly diagnosed DLBCL.

Abstract

Diffuse large B-cell lymphoma (DLBCL) remains the most common subtype of non-Hodgkin lymphoma. While standard immunochemotherapy achieves high cure rates, up to 40% of patients experience relapsed or refractory (r/r) disease, highlighting the need for novel strategies. This review outlines emerging targeted therapies and immunotherapeutic approaches, excluding CAR-T. Bispecific antibodies have shown impressive efficacy, especially in combination with antibody–drug conjugates (ADCs), and are now being investigated in frontline DLBCL in combination with chemotherapy. ADCs like polatuzumab vedotin and loncastuximab tesirine have expanded treatment options in both first-line and salvage therapy. Combination therapy of small-molecule inhibitors—including BTK, BCL2, and EZH2 inhibitors—has efficacy in genomically defined subgroups. Collectively, these agents provide promising treatment options for patients with r/r DLBCL. Ongoing efforts are needed to elucidate long-term efficacy in newly diagnosed DLBCL, determine optimal sequencing of novel therapies in r/r DLBCL, and better expand access to bispecific antibodies across the globe.

1. Introduction

1.1. DLBCL Epidemiology and Subtypes

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL). It comprises approximately 25% of all NHL cases [1]. In the United States, SEER data from 2018 to 2022 indicate that DLBCL had an age-adjusted incidence rate of 5.6 per 100,000 persons annually and a corresponding mortality rate of 1.7 per 100,000 [2]. Over 50% of cases were observed in individuals between 55 and 74 years of age [2]. The prognosis for patients with DLBCL can vary significantly, influenced by stage, International Prognostic Index (IPI) score, molecular subtype, and other comorbid conditions [1]. Efforts to subclassify DLBCL on the basis of cell of origin via immunohistochemistry (IHC) and high-grade B-cell lymphoma (HGBCL) by fluorescence in situ hybridization (FISH) have aided prognostication but are not comprehensive given the heterogeneity of these subgroups. Genomic subclassification of DLBCL by next-generation sequencing (NGS) appears to provide better prediction of therapeutic response; however, it is yet to be widely adopted in routine clinical practice [3].

1.2. Limitations of Standard Therapy and the Need for Novel Approaches in DLBCL

Despite initial responsiveness to chemoimmunotherapy, up to 30–40% of patients experience relapsed or refractory (R/R) disease [3]. Historically, salvage chemoimmunotherapy followed by High-Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR) was the treatment of choice for transplant-eligible R/R DLBCL patients [3]. However, patients with relapsed or refractory (R/R) DLBCL often have chemo-refractory disease or are not candidates for the rigor of transplant. Chimeric antigen receptor T-cells (CAR-T) have shown great efficacy with durable remissions in 30–40% of R/R DLBCL patients [4,5,6,7]; however, there are many real-world barriers to CAR-T therapy, including patient frailty or significant comorbidities, patient’s geographic proximity to a CAR-T center, cost of therapy, lack of caregiver support, and prolonged manufacturing times for those with rapid disease progression [8]. Additionally, adverse events (AEs) of CAR-T are also significant, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), prolonged cytopenias, and infections. These challenges underscore the need for less toxic therapies that can be readily accessible and efficacious yet tolerable for older, frail patients [3]. Recently, bispecific antibodies and antibody–drug conjugates have shown promise in these regards [9]. In this article, we will review the evolving landscape of targeted therapies and emerging immunotherapeutic approaches (excluding CAR-T) in the management of DLBCL.

2. Bispecific Antibodies

Bispecific antibodies (BsAbs) are engineered monoclonal antibodies designed to simultaneously bind two distinct antigens, enabling them to bridge different cell types or molecules. A structural configuration often features a single antibody fragment (Fab) containing both CD20- and CD3-binding sites arranged in a head-to-tail orientation, which enables them to engage with T-cells by binding to the CD3ε subunit of the T-cell receptor complex while simultaneously binding to the specific cell surface tumor antigen (CD20) on the target cancer cell (Figure 1). They induce T-cell activation through an MHC-independent mechanism without requiring antigen presentation via the MHC complex and T-cell receptor specificity. Once activated, these T-cells mediate cytotoxic responses against tumor cells through perforin and granzyme release [10]. Below is an overview of the most clinically advanced and approved bispecific antibodies, summarizing their pivotal trial data, efficacy outcomes, and safety profiles (Table 1 and Table 2).

2.1. Epcoritamab

Epcoritamab is a bispecific IgG1 monoclonal antibody designed to engage CD3 on T cells and CD20 on B cells, thereby promoting T-cell–mediated cytotoxicity against CD20-positive malignancies. In a phase I/II study of heavily pretreated relapsed/refractory (R/R) large B-cell lymphoma, single-agent epcoritamab achieved an overall response rate of ~63% with ~39% complete responses, demonstrating deep and durable remissions even in patients who had prior CAR T-cell therapy [11]. The treatment’s safety profile is manageable; the most common adverse effects are CRS (49.7%) (primarily grade 1–2, 2% grade 3+), injection site reaction, and neutropenia. ICANS is infrequent (seen in <10% of patients and typically low grade). This pivotal trial led to FDA approval in 3L+ DLCBL [11]. Epcoritamab is being investigated in various settings: in salvage therapy for transplant-eligible high-risk DLBCL, its combination with R-DHAX/C has produced high response rates (≥70% CR), and many patients proceeded to transplant [12,13]; in transplant-ineligible R/R DLBCL, epcoritamab combined with gemcitabine–oxaliplatin (GemOx) chemotherapy yielded an ORR of approximately 82% (with ~54% CR) in a phase II trial [14,15]. Promising results have also been seen in front-line therapy for patients unfit for standard R-CHOP: adding epcoritamab to an attenuated R-mini-CHOP regimen led to 89% overall response (82% CR) in an initial cohort of elderly/frail untreated DLBCL patients [16]. A recent study with the epcoritamab + R-ICE combination demonstrated high CR (65%) rates in pts with R/R DLBCL eligible for ASCT [17]. Epcoritamab and Pola-R-CHP combination in newly diagnosed DLBCL showed high ORR (100%) and CR (97%) in all subgroups of DLBCL with no high-grade CRS [19]. Novel chemo-free combinations are under exploration as well—for instance, fixed-duration epcoritamab plus lenalidomide has shown encouraging activity in R/R DLBCL [18]. Ongoing studies are broadening the scope of epcoritamab’s application, including a randomized phase III trial comparing epcoritamab to standard-of-care salvage regimens (investigator’s choice of rituximab–gemcitabine–oxaliplatin or bendamustine–rituximab) in R/R DLBCL [22].

2.2. Glofitamab

Glofitamab is a CD20 × CD3 T-cell engaging bispecific antibody designed with a novel 2:1 structural format, with two regions that bind to CD20 on B cells and one region that binds to CD3 on T cells. In the pivotal phase II study, glofitamab monotherapy in relapsed/refractory (R/R) DLBCL achieved an overall response rate (ORR) of 52% and complete response (CR) rate of 39%, with a manageable safety profile dominated by low-grade cytokine release syndrome (CRS). Extended follow-up demonstrated that responses were durable, with a median CR duration of 24.1 months and 38% of patients remaining in CR at 3 years [24,25,26]. These data led to FDA approval of glofitamab in 3L + DLBCL. Importantly, glofitamab has shown efficacy in patients who relapsed after CAR-T therapy, as demonstrated in a LYSA phase II trial [27]. In the phase III STARGLO study, glofitamab plus GemOx significantly improved median overall survival (25.5 vs. 12.9 months) and CR rates (58.5% vs. 25.3%) versus R-GemOx in transplant-ineligible R/R DLBCL with sustained response in updated 2-year outcomes [116]. Though approved by the European Medical Association and incorporated into NCCN guidelines in the second-line setting, the combination was not FDA-approved due to low US patient representation in the trial [23]. Glofitamab–polatuzumab vedotin combination showed a CR rate of 59% and sustained remissions in high-risk populations, including those with high-grade B-cell lymphoma and prior CAR-T exposure [28]. A phase Ib study of glofitamab + Pola-R-CHP in untreated DLBCL demonstrated promising efficacy and tolerability [29], and the ongoing SKYGLO phase III trial is assessing this combination in a randomized setting [30]. Similarly, the addition of glofitamab to R-CHOP in newly diagnosed high-risk DLBCL (defined by ctDNA dynamics) resulted in high response rates and a favorable safety profile in the phase I study [31]. In the transplant-eligible setting, glofitamab combined with R-ICE has shown efficacy and manageable toxicity, supporting its use in bridging or salvage strategies [32]. The COALITION trial and its randomized phase II follow-up showed that frontline glofitamab-containing regimens yielded deep and durable metabolic remissions [34,35]. Additionally, at EHA 2025, a separate phase II study evaluating the glofitamab–rituximab–polatuzumab combination in patients unfit for R-CHOP revealed high ORR with fewer adverse effects [117,118].

2.3. Odronextamab

Odronextamab is an off-the-shelf CD20 × CD3 bispecific antibody demonstrating promising efficacy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including after CAR T-cell therapy. In the phase I ELM-1 study, single-agent odronextamab achieved an ORR of 49% and a CR rate of 31% in patients with DLBCL who progressed post-CAR T, with durable responses and manageable cytokine release syndrome (CRS) through step-up dosing [36]. In the phase II ELM-2 trial, odronextamab achieved an ORR of 52% and a CR rate of 31% in heavily pretreated R/R DLBCL patients (≥2 lines of therapy), with a median duration of response of 9.5 months [37]. Ongoing phase III trials are now evaluating odronextamab in earlier lines of therapy: OLYMPIA-3 is comparing odronextamab-CHOP to R-CHOP in newly diagnosed DLBCL [38], while OLYMPIA-4 is assessing odronextamab vs. standard-of-care regimens in R/R aggressive B-cell lymphoma [39].

2.4. Mosunetuzumab

Mosunetuzumab, a CD20 × CD3 bispecific antibody, has demonstrated significant therapeutic potential in diffuse large B-cell lymphoma (DLBCL) across various clinical contexts. As a single agent, it is both active and tolerable for patients with relapsed or refractory (R/R) disease [40] and has yielded promising, durable complete responses in elderly or unfit patients as a first-line treatment [42]. When used as monotherapy, the most common adverse events include cytokine release syndrome (CRS), occurring in approximately 26–29% of patients (predominantly low-grade and early in treatment), and grade 3–4 neutropenia, seen in about 10–13% of elderly/unfit patients. The utility of mosunetuzumab extends to combination therapies, where it has shown favorable safety and efficacy when paired with CHOP chemotherapy for previously untreated patients [41]. In a phase 1b/2 trial, Mosun-Pola achieved an ORR of 59% and a CR rate of 45.9%, with responses observed in patients previously treated with CAR-T therapy [38]. A randomized phase II study further highlighted its superiority over rituximab plus polatuzumab, with higher ORR (78% vs. 50%) and CR rates (58% vs. 35%) [43,44]. Common adverse events for this combination are generally manageable and include grade 3–4 neutropenia (20–30% of patients), fatigue (~35–43%), and low-grade CRS (10–18%) [43,44]. This promising regimen is being further evaluated in the phase III SUNMO trial, showing a median PFS of 11.5 months vs. 3.8 months with 25.9% CRS (<1% grade 3) [45]. The low rate of high-grade CRS with mosun/pola makes this combination appealing for outpatient administration, potentially facilitating future uptake in the community setting. The versatility of mosunetuzumab is underscored by ongoing clinical trials exploring novel combinations with agents such as loncastuximab tesirine [42] and a triplet regimen with polatuzumab vedotin and lenalidomide, reflecting its growing importance in the DLBCL treatment [41].

2.5. Planotamab

Plamotamab is another CD20 × CD3 bispecific antibody, which is currently under investigation for relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. In the phase I study, intravenous plamotamab achieved an ORR of 47% and a CR rate of 26% in a heavily pretreated population [49]. Cytokine release syndrome (CRS) occurred in 57% of patients, although 94% of events were grade 1–2 and only 3% experienced grade ≥ 3 CRS. Other common treatment-emergent adverse events included pyrexia (57%), chills (35%), and neutropenia (32%) [49]. A 2024 update demonstrated that subcutaneous administration was well tolerated, with no new safety signals and lower peak cytokine levels compared to intravenous dosing [50]. Plamotamab is now being evaluated in a randomized phase II trial in combination with tafasitamab and lenalidomide vs. tafasitamab–lenalidomide in R/R DLBCL [51].

2.6. Blinatumomab

Blinatumomab, a CD19 × CD3 bispecific T-cell engager, has demonstrated modest single-agent activity in DLBCL. In a phase II study of relapsed/refractory (R/R) DLBCL, blinatumomab achieved an ORR of 43% and a CR rate of 19%, but responses were typically short-lived (median duration: 2.9 months). Adverse events were frequent, with CRS occurring in 37% and neurologic events in 58% of patients, including 22% with grade ≥ 3 neurotoxicity [52]. To enhance efficacy and reduce relapses, combination strategies have been pursued. In a phase Ib trial, blinatumomab-pembrolizumab showed an ORR of 36%, with improved outcomes in PD-L1–positive tumors [53]. As consolidation post-autologous stem cell transplant, blinatumomab was associated with a 1-year progression-free survival of 72% and low-grade CRS and neurologic toxicity in <10% of patients [54]. In newly diagnosed high-risk DLBCL, blinatumomab post–R-CHOP demonstrated feasibility with manageable safety—grade ≥ 3 neurologic events occurred in ~10% [55]. Ongoing trials are also evaluating its combination with lenalidomide to enhance T-cell activation in R/R non-Hodgkin lymphoma [56]. The limited durability of response, toxicities, and logistics of continuous infusion have limited the clinical uptake of blinatumomab as monotherapy in DLBCL.
Despite the promising efficacy of bispecific antibodies, especially in combination with chemotherapy or ADCs, their widespread adoption has been limited due to multiple challenges, namely clinical and logistical barriers, particularly for standalone community practices. Inpatient admission for step-up dosing can be burdensome, especially for sites new to bispecific administration without an affiliated hospital. Inpatient and outpatient multidisciplinary teams and workflows are critical in early identification and management of CRS and ICANS but can be challenging to establish across multiple sites. Strategies to mitigate CRS and ICANS risks, such as subcutaneous administration, prephase steroids or obinutuzumab, and combination with chemotherapy or ADCs, appear to reduce risks and allow more patients to be treated in the outpatient setting. Infection risk is an ongoing challenge, especially for indefinite therapies. Ongoing efforts such as prophylactic immune globulin administration have proven to reduce infection risk in BCMA-directed bispecifics, but further investigation is needed in lymphoma [119].
Optimal patient selection and sequencing of therapies are rapidly evolving areas of investigation. With the plethora of clinical trials investigating bispecific antibody use in earlier lines of therapy, ideal combination strategies will be challenging to select without randomized trials. For patients treated with bispecific antibodies in early lines of therapy, it will be crucial to study the impact on subsequent therapies, namely CAR-T, as there are potential concerns regarding T-cell fitness and exhaustion. There are preliminary retrospective data from the French DESCAR-T registry suggesting similar response rates and survival for bispecific-treated and bispecific-naïve patients who went on to receive subsequent CAR-T, but further investigation is warranted [120]. Translational efforts will be critical to assess the role of molecular subtypes and tumor microenvironment on outcomes, ideally influencing optimal patient selection. For example, a multicenter retrospective cohort found dismal outcomes with epcoritamab and glofitamab in CD20-negative patients, with a median PFS of 1.3 months and a median OS of 2.0 months [121].

3. Checkpoint Inhibitors

3.1. Atezolizumab

Atezolizumab, a PD-L1 immune checkpoint inhibitor, has been explored in multiple settings in diffuse large B-cell lymphoma (DLBCL). In the consolidation setting, a phase II study evaluated atezolizumab in high-risk DLBCL patients in complete remission after R-CHOP, reporting a 2-year progression-free survival of 72.4% [57]. A phase Ib trial combining atezolizumab and obinutuzumab in R/R DLBCL showed an overall response rate (ORR) of 17%, with manageable toxicity [58]. Another phase Ib study of atezolizumab plus tazemetostat reported an ORR of 16%, with responses more frequent in EZH2-mutant tumors [59]. In the frontline setting, atezolizumab added to R-CHOP showed a CR rate of 77% and 2-year PFS of 70%, though with increased immune-related adverse events such as rash (27%) and transaminitis (18%) [60]. For transformed or Richter’s DLBCL, combinations with venetoclax and obinutuzumab (MOLTO trial) achieved ORRs of 67–74% [62,63]. While the efficacy of atezolizumab as monotherapy remains limited, its combination with other chemo/immunotherapy agents has shown promising results.

3.2. Durvalumab

Durvalumab, a PD-L1 checkpoint inhibitor, is being explored primarily as a combination regimen in diffuse large B-cell lymphoma (DLBCL). In a phase II study, durvalumab combined with R-CHOP or with lenalidomide plus R-CHOP was evaluated in previously untreated high-risk DLBCL patients, demonstrating acceptable safety and feasibility, though detailed efficacy (ORR 54–67%) data were limited [66]. Additionally, a phase I study assessed durvalumab with the CD19-targeted antibody–drug conjugate loncastuximab tesirine in relapsed/refractory B-cell lymphomas, including DLBCL, showing preliminary anti-tumor activity with manageable toxicity [67]. While early results are promising, durvalumab’s role in DLBCL remains investigational.

3.3. Pembrolizumab

Pembrolizumab is a PD-1 immune checkpoint inhibitor, which has revealed limited efficacy as monotherapy in relapsed/refractory (R/R) DLBCL with response rates around 20% [71]. However, it has shown greater efficacy in select subtypes; in the final analysis of KEYNOTE-170, pembrolizumab achieved an overall response rate (ORR) of 41% and a complete response (CR) rate of 20% in relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL), with durable responses and manageable toxicity [68]. In the PORTIA phase Ib study, pembrolizumab given with CAR T-cell therapy (tisagenlecleucel) improved the expansion and persistence of CAR T cells, with a 50% ORR and acceptable safety profile [70]. Combinations with BCR inhibitors (e.g., acalabrutinib) or HDAC inhibitors (e.g., vorinostat) in R/R DLBCL have also yielded ORRs ranging from 26% to 55%, with enhanced responses observed in patients with PD-L1 expression [73,74]. Moreover, pembrolizumab is being explored in frontline therapy; in a phase I trial combining it with R-CHOP, a 2-year progression-free survival of 83% and a CR rate of 77% were observed in treatment-naïve DLBCL [76]. It is also under investigation for patients relapsing after CAR T-cell therapy, where it may enhance immune reactivation [78].

3.4. Nivolumab

Nivolumab, a PD-1 immune checkpoint inhibitor, has shown modest activity in diffuse large B-cell lymphoma (DLBCL), particularly in select subsets and in combination regimens. In a phase II study of patients with relapsed/refractory DLBCL ineligible for or relapsed after autologous stem cell transplant, nivolumab monotherapy achieved an overall response rate (ORR) of 10%, with a median duration of response of 11 months, indicating limited single-agent efficacy [79]. However, it has shown greater efficacy in combination regimens. The BeGeRN regimen (nivolumab with bendamustine, gemcitabine, and rituximab) showed modest responses (ORR 45%) in heavily pretreated patients with R/R B-cell lymphoma [80]. In high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, nivolumab consolidation after DA-EPOCH-R induction was well tolerated and showed 61% CMR [81]. The CheckMate 436 trial showed that the nivolumab–brentuximab vedotin combination in relapsed/refractory primary mediastinal large B-cell lymphoma yielded an ORR of 70% and a CR rate of 43% [82].

4. Antibody–Drug Conjugates

4.1. Polatuzumab Vedotin

Polatuzumab vedotin (Pola), an antibody–drug conjugate targeting CD79b, has reshaped frontline therapy for diffuse large B-cell lymphoma (DLBCL) through the landmark POLARIX trial. This phase III study compared Pola-R-CHP (polatuzumab, rituximab, cyclophosphamide, doxorubicin, and prednisone) against standard of care R-CHOP in previously untreated intermediate- to high-risk DLBCL. At the 5-year follow-up, Pola-R-CHP demonstrated a sustained progression-free survival (PFS) benefit, with a 5-year PFS of 70.2% vs. 62.4% for R-CHOP (hazard ratio 0.73) [83,84]. Notably, in post hoc subgroup analyses, the magnitude of benefit was more pronounced in patients with higher IPI scores (3–5), double-expressor lymphoma, and the non-GCB subtype, though genomic clustering appears to better delineate the C5 cluster with a vastly superior response to Pola-R-CHP [83,84,122]. While overall survival (OS) remained similar between arms (5-year OS ~78% in both groups), the Pola-R-CHP arm significantly reduced the risk of relapse or progression with a comparable safety profile and delayed the need for subsequent therapies [83,84]. These durable results confirm that Pola-R-CHP offers a long-term disease control advantage and support its use as a new standard of care in frontline DLBCL. Beyond the frontline setting, polatuzumab has also shown efficacy in various combinations for relapsed/refractory DLBCL, including with bendamustine–rituximab [85], venetoclax [100], bispecific antibodies, and salvage chemotherapy regimens such as Pola-R-GemOx [87] and Pola-R-ICE [91,92]. The predominant additional toxicity appears to be neuropathy, mostly low grade.

4.2. Loncastuximab Tesirine

Loncastuximab tesirine (Lonca) is an antibody–drug conjugate targeting CD19, approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 prior therapies. In the pivotal phase II LOTIS-2 trial, Lonca demonstrated an ORR of 48% and a CR rate of 25%, with a median duration of response of 13.4 months [101]. This study led to its accelerated approval for R/R DLBCL in 2021. Combination strategies are under investigation to enhance efficacy: in the LOTIS-3 trial, Lonca + ibrutinib showed preliminary ORRs of 57% in R/R DLBCL patients, including those with prior CAR T-cell therapy [102]. Lonca is being evaluated in combination therapies as well, including Lonca + rituximab (Lonca-R) vs. R-GemOx [103], Lonca-Pola, and Lonca-Mosun [104]. The LORELY phase II study is evaluating Lonca in patients with progressive disease after CAR T-cell therapy, highlighting its potential as a salvage option in post-cell therapy failure settings [105]. The LOTIS-7 trial of lonca + glofitamab showed a promising ORR of 93.3% (86.7% CR) with 41% CRS (2.4% G3) and 7.3% low-grade ICANS, suggesting a potential new combination strategy for transplant-ineligible patients unable to receive CAR-T [123].

4.3. Brentuximab Vedotin

Brentuximab vedotin (BV), an antibody–drug conjugate targeting CD30, has shown clinical activity in diffuse large B-cell lymphoma (DLBCL), particularly in CD30-expressing tumors. In a phase II study, BV monotherapy in relapsed/refractory DLBCL achieved a modest response (ORR 44%, CR 17%) [106]. However, in the ECHELON-3 trial, brentuximab vedotin (BV) combined with lenalidomide and rituximab achieved an overall response rate (ORR) of 64% and a complete response (CR) rate of 40% in heavily pretreated relapsed/refractory DLBCL patients [107]. Common adverse events included neutropenia (43%), fatigue (36%), and diarrhea (30%); grade ≥ 3 events occurred in 67%, with peripheral neuropathy in 18%—mostly low grade [107]. Further studies of BV in combination with R-CHP are ongoing [108,109].

4.4. Zilovertamab Vedotin

Zilovertamab vedotin (ZV) is an antibody–drug conjugate targeting ROR1, which is being evaluated in diffuse large B-cell lymphoma (DLBCL). In the waveLINE-004 phase II study, ZV monotherapy in relapsed/refractory DLBCL achieved a modest response (ORR 30%, CR 10%) with manageable toxicity; the most common adverse events were neutropenia, fatigue, and peripheral neuropathy [114]. Ongoing trials are exploring ZV in combination with R-CHP in both frontline (waveLINE-010) [111] and GCB-subtype-specific [110] settings, as well as in relapsed/refractory disease in combination with R-GemOx (waveLINE-003) [113]. These studies aim to establish ZV as a novel ROR1-directed therapy across DLBCL treatment lines.

4.5. Naratuximab Emtansine

Naratuximab emtansine is an antibody–drug conjugate against CD37, a lymphocyte surface marker expressed in B-NHL, linked to a cytotoxic maytansinoid, DM1. In the phase 2 trial, the combination of naratuximab plus rituximab showed modest efficacy of 44% with a CR of 24% in patients with R/R DLBCL who were not candidates for transplant and failed prior lines of therapy [115]. However, no further clinical trials are going on at this point in time.
Table 2. Efficacy and safety outcomes of select novel therapies in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Table 2. Efficacy and safety outcomes of select novel therapies in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Trial/RegimenIndication/LineN (Active Arm)ORR (%)CR (%)Median PFS (Months)Median OS (Months)CRS (Any Grade, %)CRS (Grade 3+, %)ICANS (Any Grade, %)ICANS (Grade 3+, %)
Epcoritamab Monotherapy (EPCORE NHL-1) [11]3L+ R/R DLBCL/LBCL15763.139.54.2 (overall); 37.3 (CR pts)18.5 (overall); NR (CR pts)512.5–36–6.40.6 (1 fatal event)
Epcoritamab + GemOx (EPCORE NHL-2)
[15]		2L+ ASCT-ineligible R/R DLBCL103856111.2 (overall); 26.7 (CR pts)21.6 (overall); NR (CR pts)5212.91 (G3)
Glofitamab Monotherapy (NP30179) [24,25,26]3L+ R/R DLBCL/LBCL15559381-yr PFS in CR: 71%
PFS—CR at EOT 80%		NR (18-mo OS: 41%; 1-yr OS in CR: 92%)64483
Glofitamab + GemOx (STARGLO) [23]2L+ R/R DLBCL (ASCT-ineligible)183 (Glofit-GemOx arm)68.358.513.825·5 (18·3–NE)44.82.32.30.6
Mosunetuzumab + Polatuzumab Vedotin (Phase 1b/2, NCT03671018) [43,44]2L+ R/R LBCL98 (Phase 2 expansion)59.245.911.423.316.73.11 (G2 seizure)Not reported
Mosunetuzumab + Polatuzumab Vedotin (SUNMO) [45,46]2L+ R/R aNHL (DLBCL, HGBCL, trFL, FL3B)138 (NCT05171647)70.351.411.5 months23.2 months25.90.700
Polatuzumab Vedotin + Bendamustine + Rituximab (Pola-BR, GO29365) [85]3L+ R/R DLBCL (ASCT-ineligible)4062.552.59.2 month12.4N/AN/AN/AN/A
Polatuzumab Vedotin + R-GemOx (POLARGO) [87]R/R DLBCL (ASCT-ineligible)Not specified52.740.37.419.5N/AN/AN/AN/A
Loncastuximab Tesirine Monotherapy (LOTIS-2) [101]3L+ R/R DLBCL/LBCL14548.324.84.9(1-yr EFS 54%)9.5 (1-yr OS 74%)N/AN/AN/AN/A
Brentuximab Vedotin + Lenalidomide + Rituximab (ECHELON-3) [107]3L+ R/R DLBCL (ASCT/CAR-T ineligible)15570.945.65.815.9N/AN/AN/AN/A
ViPOR (Venetoclax + Ibrutinib + Prednisone + Obinutuzumab + Lenalidomide) [124]R/R DLBCL505438Not reported (2-yr PFS 34%)Not reported (2-yr OS 36%)N/AN/AN/AN/A
Abbreviations: R/R = relapsed/refractory; DLBCL = diffuse large B-cell lymphoma; LBCL = large B-cell lymphoma; ASCT = autologous stem cell transplant; CR = complete response; ORR = overall response rate; PFS = progression-free survival; OS = overall survival; CRS = cytokine release syndrome; ICANS = immune effector cell-associated neurotoxicity syndrome; NR = not reached; NE = not estimable; N/A = not available.

5. Monoclonal Antibody

Tafasitamab

Tafasitamab is an Fc-modified, humanized monoclonal antibody (mAb) directed against the pan B-cell antigen CD19 [125]. The L-MIND trial was an important trial which led to FDA approval of tafasitamab lenalidomide combination in ASCT-ineligible patients (pts) with R/R DLBCL [126]. It showed overall ORR was 57.5% (n = 46/80), including complete response (CR) in 40% of pts. Long-term data revealed durable response with manageable safety profile. Other ongoing trials include tafasitamab + lenalidomide combination in patients with relapsed/refractory DLBCL (firmMIND) [127], tafasitamab + lenalidomide + R-CHOP vs. R-CHOP for newly diagnosed DLBCL (frontMIND) [128].

6. BTK Inhibitors

Bruton’s tyrosine kinase (BTK) is an enzyme crucial for the activation of the B-cell receptor signaling pathway. BTK inhibitors function by interfering with this pathway, thereby preventing the uncontrolled proliferation of abnormal B cells and inducing their death. In the PHOENIX trial, ibrutinib in combination with R-CHOP was evaluated for newly diagnosed non-GCB DLBCL. This study initially did not meet its primary endpoint, showing no improvement in event-free survival (EFS) in the overall intent-to-treat (ITT) or activated B-cell (ABC) DLBCL populations. However, in patients younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with slightly higher adverse events. In patients aged 60 years or older, ibrutinib plus R-CHOP was associated with increased toxicity, leading to compromised R-CHOP administration and worse outcomes [129]. More specifically, in younger patients with the MCD and N1 genetic subtypes of non-GCB DLBCL, the addition of ibrutinib to R-CHOP resulted in remarkable 100% three-year EFS and OS rates, a substantial improvement compared to R-CHOP alone (MCD: 48% EFS, 69.6% OS; N1: 50% EFS and OS) [130]. This highlights that the initial trial results, while seemingly negative, masked a clear benefit for a specific patient population, emphasizing the critical role of molecular subtyping in guiding therapy. Acalabrutinib has also shown efficacy in de novo ABC DLBCL patients in a phase 1 trial [131]. Phase 3 trials investigating acalabrutinib with R-miniCHOP vs. R-miniCHOP in older adults with untreated diffuse large B-cell lymphoma [132] and acalabrutinib with R-CHOP for patients ≤ 65 y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) [133] are ongoing as well. Zanubrutinib also showed efficacy in combination with R-CHOP for the treatment of newly diagnosed double expressor lymphoma in a phase 2 trial [134]. The nuanced efficacy of BTK inhibitors across DLBCL subtypes also suggests that combination therapies, rather than monotherapy, often yield more robust responses.
The SMART START and SMART STOP trials represent pivotal efforts to redefine frontline treatment for diffuse large B-cell lymphoma (DLBCL), particularly for high-risk and non-germinal center B-cell (non-GCB) subtypes. These trials sought to minimize the number of chemoimmunotherapy cycles by incorporating targeted therapy upfront. The SMART START trial was a phase II study that evaluated a targeted therapy combination of rituximab, lenalidomide, and ibrutinib (RLI) administered before and in conjunction with chemotherapy in newly diagnosed non-GCB DLBCL. The ORR after two cycles of RLI was 86.2%, the ORR at EOT was 100%, and the complete response rate at EOT was 94.5% with an acceptable side effect profile. It established the potential for developing biologically driven first-line therapies for DLBCL [135]. Similarly, the SMART STOP trial, a next-generation phase II trial, evaluated the combination of lenalidomide, tafasitamab, rituximab, and acalabrutinib (LTRA) in previously untreated DLBCL. Following four cycles of LTRA, the ORR was 100% and the CRR was 64%, and after an additional two cycles of LTRA-CHOP, the ORR was 100% and the CRR increased to 95%. At the end of all therapy, the CRR is 100%. The most common adverse effect was rash (13% grade 3), and 40% of patients required a dose reduction of lenalidomide. A key aspect of SMART STOP is its adaptive design: patients who achieve a complete response after four cycles of targeted therapy alone may receive only two cycles of R-CHOP instead of the standard six, and a new cohort is exploring the possibility of omitting chemotherapy entirely if deep responses are achieved with the targeted agents alone [136]. These trials have demonstrated the efficacy of targeted therapy as a frontline treatment for DLBCL.

7. BCL2 Inhibitors

The CAVALLI study (NCT02055820) investigated the BCL2 inhibitor venetoclax in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line treatment for DLBCL [137]. At the end of treatment, CR rates reached 69% across all participants, with 64% in the BCL2 IHC+ group and 66% in patients with double-expressor lymphoma (DEL). Though the 2-year PFS of 78% exceeded historical cohorts of R-CHOP alone, the increased toxicity limited ongoing study of venetoclax in frontline DLBCL [138,139].
The ViPOR trial is investigating venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide in relapsed or refractory DLBCL. It demonstrated an overall response rate of 54%, including a complete response rate of 38% [124]. The highest complete response (CR) rate, approximately 62%, was seen in patients with non-GCB diffuse large B-cell lymphoma. In comparison, CR rates were 53% among those with high-grade B-cell lymphoma featuring BCL2 rearrangement and 25% in other DLBCL subtypes [124]. ViPOR was most effective in non-GCB DLBCL, as expected from its reliance on BCR signaling and BCL2. Its activity in HGBCL-DH-BCL2 may be attributed to BCL2′s role in suppressing MYC-driven apoptosis in these tumors. ViPOR appears to be an active and well-tolerated regimen for heavily pretreated patients, though longer follow-up is needed to determine the durability of responses.

8. Tazemetostat and Tulmimetostat

Germinal center DLBCLs depend on the histone methyltransferase EZH2 to stay in a less-differentiated state, and EZH2-activating mutations may be oncogenic drivers in a subset of patients [140]. Inhibition of EZH2 leads to abnormal cell growth, resulting in cell death or differentiation and subsequent tumor regression. Tazemetostat, an oral and highly selective EZH2 inhibitor, has demonstrated antitumor efficacy in DLBCL patients with mutated (mt) or wild-type (wt) EZH2 tumors [140]. The phase II TAZ R-CHOP study (Epi-RCHOP, NCT02889523) evaluated combination therapy of tazemetostat with R-CHOP in patients 60–80 years old with newly diagnosed DLBCL, which showed 75.4% achieved a complete metabolic response (CMR) at the end of treatment with an acceptable safety profile. The estimated 18-month progression-free survival (PFS) was 77.7%, and overall survival (OS) was 88.8% [141]. Tulmimetostat (CPI-0209) is another investigational oral, next-generation, dual EZH2/EZH1 inhibitor. Further studies and clinical trials are ongoing to further evaluate their efficacy in DLBCL.

9. Selixenor

XPO1 (exportin 1) is one of the key nucleo-cytoplasmic shuttling proteins involved in the export of proteins from the nucleus to the cytoplasm. It mediates the functional inactivation of multiple tumor suppressor proteins (e.g., p53, p73, IkBκ, FOXO) and facilitates the increased translation of oncoproteins in DLBCL and is often correlated with poor prognosis [142]. Selinexor is an oral selective inhibitor of XPO1-mediated nuclear export that induces the expected nuclear accumulation and activation of tumor suppressor proteins and reduces Bcl2, Bcl-XL, and c-Myc oncoprotein concentrations [142]. The SADAL Phase 2 trial of single-agent oral selinexor showed an overall response rate of 28% and a 12% complete response with a manageable adverse event profile in patients with relapsed or refractory DLBCL who received at least two lines of previous chemoimmunotherapy [142]. The limited efficacy suggests no role for selinexor monotherapy in r/r DLBCL.

10. Conclusions

The treatment landscape for diffuse large B-cell lymphoma (DLBCL) has advanced with the introduction of targeted therapies and immunotherapies. For R/R DLBCL, bispecific antibodies, such as epcoritamab and glofitamab, have demonstrated high response rates and manageable safety profiles in R/R DLBCL, including in patients previously treated with CAR-T therapy, and can be more rapidly and widely accessible to patients at community centers. Phase III trials have shown improved outcomes of bispecific antibodies in combination with salvage chemotherapy and/or ADCs in 2L DLBCL, ushering in a new standard for patients ineligible for or unable to access CAR-T or ASCT. Ongoing studies show promise of including bispecifics in frontline DLBCL, but confirmatory phase III trials are ongoing.
Despite the promising efficacy of bispecific antibodies, ongoing challenges remain in their widespread utilization, including multidisciplinary and multi-institutional collaboration for administration and CRS/ICANS management, risk of infections, and financial toxicities.
Antibody–drug conjugates (ADCs) are also approved in frontline and R/R DLBCL. Polatuzumab has improved PFS in high-risk frontline DLBCL when combined with R-CHP and is a new standard of care in many countries/institutions. Chemo-free ADC/bispecific combinations for elderly/unfit patients are also showing early promise in ongoing trials.
Small-molecule inhibitors targeting BTK, BCL2, and EZH2 have also shown efficacy, especially in genetically defined subgroups, suggesting the importance of molecular profiling for treatment optimization. Checkpoint inhibitors have some efficacy but currently have a limited role in heavily pretreated r/r DLBCL with limited duration of response.
These targeted therapies and immunotherapies improve our treatment armamentarium for patients with DLBCL. Randomized trials are underway to determine the long-term efficacy of bispecific antibodies in combination with chemotherapy and/or ADCs in frontline and r/r DLBCL. Ongoing efforts are needed to determine optimal sequencing and combinations of these novel therapies in r/r DLBCL and to better expand access to bispecific antibodies across the globe. Ultimately, these therapies represent exciting new options for patients with DLBCL.

Author Contributions

Conceptualization, N.N.S.; writing—original draft preparation, J.C.; writing—review and editing, J.C. and N.N.S.; supervision, N.N.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

J.C.: None. N.S.: Consulting: Amgen. Speaker Bureau: Amgen, Genentech, Jazz, and Takeda. Advisory Board: Astra Zeneca, Amgen, BMS, Genentech, and Jazz.

References

  1. Modi, D.; Potugari, B.; Uberti, J. Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions. Cancers 2021, 13, 5827. [Google Scholar] [CrossRef]
  2. SEER. Diffuse Large B-Cell Lymphoma—Cancer Stat Facts. Available online: https://seer.cancer.gov/statfacts/html/dlbcl.html (accessed on 9 June 2025).
  3. Trabolsi, A.; Arumov, A.; Schatz, J.H. Bispecific antibodies and CAR-T cells: Dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 2024, 14, 27. [Google Scholar] [CrossRef]
  4. Elsawy, M.; Chavez, J.C.; Avivi, I.; Larouche, J.-F.; Wannesson, L.; Cwynarski, K.; Osman, K.; Davison, K.; Rudzki, J.D.; Dahiya, S.; et al. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood 2022, 140, 2248–2260. [Google Scholar] [CrossRef]
  5. Locke, F.L.; Ghobadi, A.; Jacobson, C.A.; Jacobsen, E.D.; Miklos, D.B.; Lekakis, L.J.; Braunschweig, I.; Oluwole, O.O.; Lin, Y.; Siddiqi, T.; et al. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. J. Clin. Oncol. 2018, 36, 3003. [Google Scholar] [CrossRef]
  6. Neelapu, S.S.; Jacobson, C.A.; Ghobadi, A.; Miklos, D.B.; Lekakis, L.J.; Oluwole, O.O.; Lin, Y.; Braunschweig, I.; Hill, B.T.; Timmerman, J.M.; et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023, 141, 2307–2315. [Google Scholar] [PubMed]
  7. Kamdar, M.K.; Solomon, S.R.; Arnason, J.; Johnston, P.B.; Glaß, B.; Bachanova, V.; Ibrahimi, S.; Mielke, S.; Mutsaers, P.; Hernandez-Ilizaliturri, F.J.; et al. Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. J. Clin. Oncol. 2024, 42 (Suppl. S16), 7013. [Google Scholar]
  8. Gajra, A.; Zalenski, A.; Sannareddy, A.; Jeune-Smith, Y.; Kapinos, K.; Kansagra, A. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice. Pharm. Med. 2022, 36, 163–171. [Google Scholar] [CrossRef] [PubMed]
  9. Westin, J.R.; Sehn, L.H. CAR T cells as a second-line therapy for large B-cell lymphoma: A paradigm shift? Blood 2022, 139, 2737–2746. [Google Scholar] [CrossRef]
  10. Falchi, L.; Vardhana, S.A.; Salles, G.A. Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities. Blood 2023, 141, 467–480. [Google Scholar] [CrossRef]
  11. Thieblemont, C.; Phillips, T.; Ghesquieres, H.; Cheah, C.Y.; Clausen, M.R.; Cunningham, D.; Do, Y.R.; Feldman, T.; Gasiorowski, R.; Jurczak, W.; et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J. Clin. Oncol. 2023, 41, 2238–2247. [Google Scholar] [CrossRef]
  12. Karimi, Y.; Abrisqueta, P.; de Vos, S.; Nijland, M.; Offner, F.; Osei-Bonsu, K.; Rana, A.; Archer, K.G.; Song, Y.; Cordoba, R.; et al. Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol. 2024, 42, 7032. [Google Scholar] [CrossRef]
  13. Abrisqueta, P.; Falchi, L.; Nijland, M.; de Vos, S.; Offner, F.; Rana, A.; Archer, K.; Song, Y.; Osei-Bonsu, K.; Karimi, Y.; et al. ABCL-272 Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease. Clin. Lymphoma Myeloma Leuk. 2024, 24, S468. [Google Scholar] [CrossRef]
  14. Brody, J.D.; Jørgensen, J.; Belada, D.; Costello, R.; Trněný, M.; Vitolo, U.; Lewis, D.J.; Karimi, Y.H.; Sureda, A.; André, M.; et al. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: Results from the EPCORE NHL-2 trial. Blood 2025, 145, 1621–1631. [Google Scholar] [CrossRef] [PubMed]
  15. Brody, J.; Joergensen, J.M.; Belada, D.; Costello, R.T.; Trněný, M.; Vitolo, U.; Lewis, D.; Karimi, Y.H.; Balari, A.M.S.; André, M.; et al. Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2. Blood 2023, 142, 3092. [Google Scholar] [CrossRef]
  16. Leslie, L.A.; Cheah, C.Y.; Morschhauser, F.; Darrah, J.M.; Brody, J.; Belada, D.; Duras, J.; Vermaat, J.S.; Musuraca, G.; Osei-Bonsu, K.; et al. Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial. Blood 2024, 144, 3106. [Google Scholar] [CrossRef]
  17. Cordoba, R. First Disclosure of Epcoritamab + R-Ice in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT): Epcore NHL-2. Available online: https://library.ehaweb.org/eha/2025/eha2025-congress/4159322/raul.cordoba.first.disclosure.of.epcoritamab.2B.r-ice.in.patients.with.relapsed.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31553%2Amarker%3D5843%2Afeatured%3D19595 (accessed on 15 June 2025).
  18. Gurion, R.; Mazza, I.A.; Thieblemont, C.; Kim, W.S.; Masszi, A.; García-Sancho, A.M.; Nagy, Z.; Tessoulin, B.; Ubieto, A.J.; Ko, P.-S.; et al. Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial. Blood 2024, 144, 3110. [Google Scholar] [CrossRef]
  19. Kerr, D.A.; Lavie, D.; Avigdor, A.; Avivi, I.; Patel, K.; Thieblemont, C.; Abrisqueta, P.; Izutsu, K.; Seliem, M.; Siddani, S.R.; et al. ABCL-417 First Data From Subcutaneous Epcoritamab + Polatuzumab Vedotin Rituximab, Cyclophosphamide Doxorubicin, and Prednisone (Pola-RCHP) for First-Line Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE NHL-5. Clin. Lymphoma Myeloma Leuk. 2024, 24, S478–S479. [Google Scholar] [CrossRef]
  20. Morschhauser, F.; Belada, D.; Duell, J.; Jurczak, W.; Kim, T.M.; Kim, W.S.; Kumode, T.; Jiménez, J.L.; Meert, C.; Alcaide, S.O.; et al. Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma. Blood 2024, 144 (Suppl. S1), 867. [Google Scholar] [CrossRef]
  21. Belada, D.; Kwiatek, M.; Burgues, J.M.B.; Morschhauser, F.; Duell, J.; Jurczak, W.; Kim, T.M.; Kim, W.S.; Kumode, T.; Jiménez, J.L.; et al. Epcore Dlbcl-3: Fixed-Duration Epcoritamab Monotherapy in Older (≥75Y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma (lbcl). Hematol. Oncol. 2025, 43 (Suppl. S3), e158_70093. [Google Scholar] [CrossRef]
  22. Thieblemont, C.; Clausen, M.R.; Balari, A.S.; Zinzani, P.L.; Fox, C.; Kim, S.Y.; Vindeloev, S.D.; Lugtenburg, P. Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol. 2021, 39 (Suppl. S15), TPS7569. [Google Scholar] [CrossRef]
  23. Abramson, J.S.; Ku, M.; Hertzberg, M.; Huang, H.-Q.; Fox, C.P.; Zhang, H.; Yoon, D.H.; Kim, W.-S.; Abdulhaq, H.; Townsend, W.; et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): A global phase 3, randomised, open-label trial. Lancet 2024, 404, 1940–1954. [Google Scholar] [CrossRef] [PubMed]
  24. Dickinson, M.J.; Carlo-Stella, C.; Morschhauser, F.; Bachy, E.; Corradini, P.; Iacoboni, G.; Khan, C.; Wróbel, T.; Offner, F.; Trněný, M.; et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2022, 387, 2220–2231. [Google Scholar] [CrossRef] [PubMed]
  25. Falchi, L.; Carlo-Stella, C.; Morschhauser, F.; Hutchings, M.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N.L.; et al. Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study. J. Clin. Oncol. 2023, 41 (Suppl. S16), 7550. [Google Scholar] [CrossRef]
  26. Dickinson, M.J.; Carlo-Stella, C.; Morschhauser, F.; Bachy, E.; Cartron, G.; Corradini, P.; Bartlett, N.L.; Iacoboni, G.; Khan, C.; Hertzberg, M.S.; et al. Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study. Blood 2024, 144, 865. [Google Scholar] [CrossRef]
  27. Cartron, G.; Houot, R.; Al Tabaa, Y.; Le Bras, F.; Ysebaert, L.; Choquet, S.; Jardin, F.; Bay, J.O.; Gros, F.X.; Morschhauser, F.; et al. Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: A phase 2 LYSA study. Nat. Cancer 2025, 6, 1173–1183. [Google Scholar] [CrossRef]
  28. Hutchings, M.; Balari, A.S.; Bosch, F.; Larsen, T.S.; Corradini, P.; Avigdor, A.; Terol, M.J.; Dominguez, A.R.; Pinto, A.; Skarbnik, A.P.; et al. Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study. Blood 2024, 144, 988. [Google Scholar] [CrossRef]
  29. Dickinson, M.; Viardot, A.; Marks, R.; Topp, M.S.; Morschhauser, F.; Jacobs, B.; Tani, M.; Bosch, F.; Esteban, D.; Cordoba, R.; et al. Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study. J. Clin. Oncol. 2023, 41, 7549. [Google Scholar] [CrossRef]
  30. Advani, R.H.; Dickinson, M.J.; Fox, C.P.; Kahl, B.; Herrera, A.F.; Lenz, G.; Song, Y.; Tao, R.; Cai, Q.; Kim, T.M.; et al. SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL). Blood 2024, 144, 1718-1. [Google Scholar] [CrossRef]
  31. Falchi, L.; Jardin, F.; Haioun, C.; Wrobel, T.; Joergensen, J.M.; Bastos-Oreiro, M.; Mou, E.; Martinez-Lopez, J.; Budde, L.E.; Bartlett, N.L.; et al. Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results. Blood 2023, 142, 858. [Google Scholar] [CrossRef]
  32. Diefenbach, C.S.; Caimi, P.F.; Saba, N.S.; Madueno, F.V.; Hamadani, M.; Fayad, L.E.; Riedell, P.A.; Gillis-Smith, A.; Simko, S.; Orellana-Noia, V.; et al. Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study. Blood 2024, 144, 987. [Google Scholar] [CrossRef]
  33. Hutchings, M.; Dickinson, M.J.; Gritti, G.; Carlo-Stella, C.; Townsend, W.; Bosch, F.; Bartlett, N.L.; Cartron, G.; Ghesquieres, H.; Houot, R.; et al. Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072. Blood 2024, 144, 990. [Google Scholar] [CrossRef]
  34. Minson, A.; Hamad, N.; Yannakou, C.K.; Wong, S.M.; Butler, J.P.; Seymour, J.F.; Dickinson, M. Trial in Progress: A Multicentre, Parallel Arm, Open-Label Trial of Frontline R-CHOP/Polatuzumab Vedotin-RCHP and Glofitamab in Younger Patients with Higher Risk Diffuse Large B Cell Lymphoma (COALITION). Blood 2021, 138, 3571. [Google Scholar] [CrossRef]
  35. Minson, A.; Verner, E.; Giri, P.; Butler, J.; Janowski, W.; Cheah, C.Y.; Ratnasingam, S.; Wong, S.M.; Ku, M.; Hertzberg, M.S.; et al. A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics. Blood 2024, 144, 582. [Google Scholar] [CrossRef]
  36. Topp, M.S.; Matasar, M.; Allan, J.N.; Ansell, S.M.; Barnes, J.A.; Arnason, J.E.; Michot, J.-M.; Goldschmidt, N.; O’bRien, S.M.; Abadi, U.; et al. Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: Primary analysis of the ELM-1 study. Blood 2025, 145, 1498–1509. [Google Scholar] [CrossRef] [PubMed]
  37. Kim, W.S.; Kim, T.M.; Cho, S.-G.; Jarque, I.; Iskierka-Jażdżewska, E.; Poon, L.M.; Prince, H.M.; Zhang, H.; Cao, J.; Zhang, M.; et al. Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: Primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat. Cancer 2025, 6, 528–539. [Google Scholar] [CrossRef] [PubMed]
  38. Matasar, M.; Turgut, B.; Tessoulin, B.; Guidez, S.; Altuntas, F.; Iqbal, N.; Namuduri, M.; Cao, A.; Sophos, N.; Uppala, A.; et al. Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL.; OLYMPIA-3). J. Clin. Oncol. 2024, 42, TPS7086. [Google Scholar] [CrossRef]
  39. Hawkes, E.A.; Kim, T.M.; Martín, E.M.D.; Núñez-García, A.; Chong, G.; Namuduri, M.; Risal, A.; Cheng, Y.; Flink, D.M.; Zhu, M.; et al. Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL.; OLYMPIA-4). J. Clin. Oncol. 2024, 42, TPS7093. [Google Scholar] [CrossRef]
  40. Bartlett, N.L.; Assouline, S.; Giri, P.; Schuster, S.J.; Cheah, C.Y.; Matasar, M.; Gregory, G.P.; Yoon, D.H.; Shadman, M.; Fay, K.; et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2023, 7, 4926–4935. [Google Scholar] [CrossRef]
  41. Olszewski, A.J.; Phillips, T.J.; Hoffmann, M.S.; Armand, P.; Kim, T.M.; Yoon, D.H.; Mehta, A.; Greil, R.; Westin, J.; Lossos, I.S.; et al. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: Safety and efficacy results from a phase 2 study. Blood Adv. 2023, 7, 6055–6065. [Google Scholar] [CrossRef]
  42. Olszewski, A.; Avigdor, A.; Babu, S.; Levi, I.; Eradat, H.; Abadi, U.; Holmes, H.; McKinney, M.; Woszczyk, D.; Giannopoulos, K.; et al. ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses. Clin. Lymphoma Myeloma. Leuk. 2021, 21, S395–S396. [Google Scholar] [CrossRef]
  43. Budde, L.E.; Olszewski, A.J.; Assouline, S.; Lossos, I.S.; Diefenbach, C.; Kamdar, M.; Ghosh, N.; Modi, D.; Sabry, W.; Naik, S.; et al. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: A phase 1b/2 trial. Nat. Med. 2023, 30, 229–239. [Google Scholar] [CrossRef]
  44. Chavez, J.C.; Olszewski, A.J.; Bastos-Oreiro, M.; Assouline, S.E.; Lossos, I.S.; Diefenbach, C.; Ghosh, N.; Modi, D.; Sabry, W.; Naik, S.; et al. A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). Blood 2024, 144, 989. [Google Scholar] [CrossRef]
  45. Westin, J.; Olszewski, A.J.; Fogliatto, L.; Kim, W.S.; Shin, H.-J.; Jeon, Y.-W.; Norasetthada, L.; Pavlovsky, A.; Rego, E.; Wu, H.; et al. SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. J. Clin. Oncol. 2023, 41 (Suppl. S16), TPS7586. [Google Scholar] [CrossRef]
  46. Westin, J.; Zhang, H.; Kim, W.; Fogliatto, L.; Maruyama, D.; Farias, D.; Norasetthada, L.; Hong, H.; Ozcan, M.; Pavlovsky, A.; et al. Mosunetuzumab Plus Polatuzumab Vedotin is Superior to R-GemOx in Transplant-Ineligible Patients with R/R Lbcl: Primary Results of The Phase III Sunmo Trial. Hematol. Oncol. 2025, 43, 1–6. [Google Scholar] [CrossRef]
  47. Kambhampati, S.; Kallam, A.; Borogovac, A.; Chen, L.; Puverel, S.; Johnson, J.; Melgar, I.; Baird, J.H.; Danilov, A.; Godfrey, J.; et al. A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood 2024, 144 (Suppl. S1), 1742-1. [Google Scholar] [CrossRef]
  48. National Cancer Institute (NCI). A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Report No.: NCT06015880. 2025. Available online: https://clinicaltrials.gov/study/NCT06015880 (accessed on 8 June 2025).
  49. Patel, K.; Riedell, P.A.; Tilly, H.; Ahmed, S.; Michot, J.M.; Ghesquieres, H.; de Colella, J.-M.S.; Khan, A.C.; Bouabdallah, K.; Tessoulin, B.; et al. A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis. Blood 2022, 140 (Suppl. S1), 9470–9472. [Google Scholar] [CrossRef]
  50. Riedell, P.A.; Patel, K.; Dunleavy, V.; Karimi, Y.H.; Shah, N.N.; Ribrag, V.; Ysebaert, L.; Noel, R.; Brisou, G.; Kline, J.; et al. Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy. Blood 2024, 144, 4497. [Google Scholar] [CrossRef]
  51. Patel, K.; Koh, Y.; Ayyappan, S.; Karimi, Y.; Lossos, I.S.; Merchant, A.; Lee, P.; Jin, J.; Clynes, R.; Kanodia, J.; et al. Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL. Blood 2022, 140, 12066–12067. [Google Scholar] [CrossRef]
  52. Viardot, A.; Goebeler, M.-E.; Hess, G.; Neumann, S.; Pfreundschuh, M.; Adrian, N.; Zettl, F.; Libicher, M.; Sayehli, C.; Stieglmaier, J.; et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 2016, 127, 1410–1416. [Google Scholar] [CrossRef]
  53. Giri, P.; Patil, S.; Ratnasingam, S.; Prince, H.M.; Milliken, S.; Meijide, J.B.; Coyle, L.; Van Der Poel, M.; Mulroney, C.M.; Farooqui, M.Z.H.; et al. Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol. 2022, 40, e19584. [Google Scholar] [CrossRef]
  54. Ghobadi, A.; Foley, N.C.; Cohen, J.; Rettig, M.P.; Cashen, A.F.; Gehrs, L.; Christ, S.; Street, E.; Wallace, N.; Ritchey, J.; et al. Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Blood Adv. 2024, 8, 513–522. [Google Scholar] [CrossRef]
  55. Katz, D.A.; Morris, J.D.; Chu, M.P.; David, K.A.; Thieblemont, C.; Morley, N.J.; Khan, S.S.; Viardot, A.; García-Sancho, A.M.; Rodríguez-García, G.; et al. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. Leuk. Lymphoma 2022, 63, 2063–2073. [Google Scholar] [CrossRef]
  56. National Cancer Institute (NCI). A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL).Report No.: NCT02568553. 2025. Available online: https://clinicaltrials.gov/study/NCT02568553 (accessed on 5 June 2025).
  57. Nijland, M.; Issa, D.E.; Bult, J.A.A.; Deeren, D.; Velders, G.A.; Nijziel, M.R.; Sandberg, Y.; Vergote, V.; Oosterveld, M.; Fijnheer, R.; et al. Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP. Blood Adv. 2025, 9, 3530–3539. [Google Scholar] [CrossRef]
  58. Palomba, M.L.; Till, B.G.; Park, S.I.; Morschhauser, F.; Cartron, G.; Marks, R.; Shivhare, M.; Hong, W.-J.; Raval, A.; Chang, A.C.; et al. Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study. Clin. Lymphoma Myeloma Leuk. 2022, 22, e443–e451. [Google Scholar] [CrossRef]
  59. Palomba, M.L.; Cartron, G.; Popplewell, L.; Ribrag, V.; Westin, J.; Huw, L.-Y.; Agarwal, S.; Shivhare, M.; Hong, W.-J.; Raval, A.; et al. Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study. Clin. Lymphoma Myeloma Leuk. 2022, 22, 504–512. [Google Scholar] [CrossRef] [PubMed]
  60. Younes, A.; Burke, J.M.; Cheson, B.D.; Diefenbach, C.S.; Ferrari, S.; Hahn, U.H.; Hawkes, E.A.; Khan, C.; Lossos, I.S.; Musuraca, G.; et al. Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma. Blood Adv. 2023, 7, 1488–1495. [Google Scholar] [CrossRef] [PubMed]
  61. Othman, T.; Frankel, P.; Allen, P.; Popplewell, L.L.; Shouse, G.; Siddiqi, T.; Danilov, A.V.; Ruel, N.; Daniels, S.; Peters, L.; et al. Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica 2024, 110, 142–152. [Google Scholar] [CrossRef] [PubMed]
  62. Tedeschi, A.; Frustaci, A.M.; Condoluci, A.; Coscia, M.; Chiarle, R.; Zinzani, P.L.; Motta, M.; Gaidano, G.; Quaresmini, G.; Scarfò, L.; et al. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024, 25, 1298–1309. [Google Scholar] [CrossRef]
  63. Frustaci, A.M.; Montillo, M.; Rossi, D.; Zinzani, P.L.; Motta, M.; Gaidano, G.; Quaresmini, G.; Scarfo, L.; Pietrasanta, D.; Coscia, M.; et al. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome. J. Clin. Oncol. 2023, 41 (Suppl. S16), 7502. [Google Scholar] [CrossRef]
  64. Herbaux, C.; Bachy, E.; Bouabdallah, R.; Guidez, S.; Casasnovas, O.; Feugier, P.; Damaj, G.; Tilly, H.; Ysebaert, L.; Le Gouill, S.; et al. Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group. Br. J. Haematol. 2025, 207, 110–122. [Google Scholar] [CrossRef]
  65. Herbaux, C.; Casasnovas, O.; Feugier, P.; Damaj, G.; Bouabdallah, R.; Guidez, S.; Ysebaert, L.; Tilly, H.; Le Gouill, S.; Fornecker, L.; et al. Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA. J. Clin. Oncol. 2020, 38, 8053. [Google Scholar] [CrossRef]
  66. Jaeger, U.; Kalakonda, N.; Everaus, H.; Fustier, P.; Jaeger, J.; Manzke, O.; Nowakowski, G.S. Phase II Study of Durvalumab (anti–Pd-L1) Combined with Either R-Chop or Lenalidomide and R-Chop in Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma. Hematol. Oncol. 2017, 35 (Suppl. S2), 419–420. [Google Scholar] [CrossRef]
  67. Moskowitz, C.H.; Bastos-Oreiro, M.; Ungar, D.; Dautaj, I.; Kalac, M. Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma. Blood 2019, 134, 2807. [Google Scholar] [CrossRef]
  68. Zinzani, P.L.; Thieblemont, C.; Melnichenko, V.; Bouabdallah, K.; Walewski, J.; Majlis, A.; Fogliatto, L.M.; Garcia-Sancho, A.M.; Christian, B.; Gulbas, Z.; et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170. Blood 2023, 142, 141–145. [Google Scholar] [CrossRef] [PubMed]
  69. Wang, Y.; LaPlant, B.R.; Parikh, S.A.; Leis, J.F.; Call, T.G.; Shanafelt, T.D.; He, R.; Micallef, I.N.; Nowakowski, G.S.; Habermann, T.M.; et al. Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL). J. Clin. Oncol. 2024, 42, 7050. [Google Scholar] [CrossRef]
  70. Jaeger, U.; Worel, N.; McGuirk, J.P.; Riedell, P.A.; Fleury, I.; Du, Y.; Han, X.; Pearson, D.; Redondo, S.; Waller, E.K. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: Phase 1b PORTIA study results. Blood Adv. 2023, 7, 2283–2286. [Google Scholar] [CrossRef]
  71. Kuruvilla, J.; Armand, P.; Hamadani, M.; Kline, J.; Moskowitz, C.H.; Avigan, D.; Brody, J.D.; Ribrag, V.; Herrera, A.F.; Morschhauser, F.; et al. Pembrolizumab for patients with non-Hodgkin lymphoma: Phase 1b KEYNOTE-013 study. Leuk. Lymphoma 2022, 64, 130–139. [Google Scholar] [CrossRef]
  72. Gregory, G.P.; Kumar, S.K.; Wang, D.; Mahadevan, D.; Walker, P.; Wagner-Johnston, N.D.; Escobar, C.; Bannerji, R.; Bhutani, D.; Chang, J.; et al. Pembrolizumab plus dinaciclib in patients with hematologic malignancies: The phase 1b KEYNOTE-155 study. Blood Adv. 2022, 6, 1232–1242. [Google Scholar] [CrossRef]
  73. Godfrey, J.; Mei, M.; Chen, L.; Song, J.Y.; Bedell, V.; Budde, E.; Armenian, S.; Puverel, S.; Nikolaenko, L.; Chen, R.; et al. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma. Haematologica 2023, 109, 533–542. [Google Scholar] [CrossRef]
  74. Witzig, T.E.; Maddocks, K.J.; De Vos, S.; Lyons, R.M.; Edenfield, W.J.; Sharman, J.P.; Vose, J.; Yimer, H.A.; Wei, H.; Chan, E.M.; et al. Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol. 2019, 37, 7519. [Google Scholar] [CrossRef]
  75. Berinstein, N. Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study. In Proceedings of the 62nd ASH Annual Meeting and Exposition, San Diego, CA, USA, 5–8 December 2020; Available online: https://ash.confex.com/ash/2020/webprogram/Paper136751.html (accessed on 7 June 2025).
  76. Ho, C.; Fromm, J.R.; Fang, M.; Till, B.G.; Shadman, M.; Cowan, A.; Lynch, R.C.; Wu, V.; Voutsinas, J.M.; Rasmussen, H.A.; et al. Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL. J. Clin. Oncol. 2023, 41 (Suppl. S16), 7561. [Google Scholar] [CrossRef]
  77. Chong, E.A.; Alanio, C.; Svoboda, J.; Nasta, S.D.; Landsburg, D.J.; Lacey, S.F.; Ruella, M.; Bhattacharyya, S.; Wherry, E.J.; Schuster, S.J. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood 2022, 139, 1026–1038. [Google Scholar] [CrossRef]
  78. Osborne, W.; Marzolini, M.; Tholouli, E.; Ramakrishnan, A.; Bachier, C.R.; McSweeney, P.A.; Irvine, D.; Zhang, M.; Al-Hajj, M.A.; Pule, M.; et al. Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL. J. Clin. Oncol. 2020, 38 (Suppl. S15), 8001. [Google Scholar] [CrossRef]
  79. Ansell, S.M.; Minnema, M.C.; Johnson, P.; Timmerman, J.M.; Armand, P.; Shipp, M.A.; Rodig, S.J.; Ligon, A.H.; Roemer, M.G.; Reddy, N.; et al. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. J. Clin. Oncol. 2019, 37, 481–489. [Google Scholar] [CrossRef]
  80. Smykova, O.G.; Markelov, V.V.; Lepik, K.V.; Kondakova, E.V.; Stelmakh, L.V.; Moiseev, I.S.; Mikhailova, N.B.; Kulagin, A.D. LY-07. Immunochemotherapy with nivolumab, bendamustine, gemcitabine and rituximab (BeGeRN) in relapsed or refractory B-cell Non-Hodgkin Lymphoma: NCT03259529. Cell. Ther. Transplant. 2022, 11, 1–132. [Google Scholar] [CrossRef]
  81. de Jonge, A.V.; van Werkhoven, E.D.; Nijland, M.; de Heer, K.; Van Der Poel, M.W.; Sandberg, Y.; Klerk, C.; Drees, E.E.; Roemer, M.G.; de Jong, D.; et al. High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial. Blood 2021, 138, 1414. [Google Scholar] [CrossRef]
  82. Zinzani, P.L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P.M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N.A.; Mehta-Shah, N.; et al. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. J. Clin. Oncol. 2019, 37, 3081–3089. [Google Scholar] [CrossRef] [PubMed]
  83. Salles, G.; Morschhauser, F.; Sehn, L.H.; Herrera, A.F.; Friedberg, J.W.; Trněný, M.; Lenz, G.; Sharman, J.P.; Herbaux, C.; Burke, J.M.; et al. Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes. Blood 2024, 144, 469. [Google Scholar] [CrossRef]
  84. Tilly, H.; Morschhauser, F.; Sehn, L.H.; Friedberg, J.W.; Trněný, M.; Sharman, J.P.; Herbaux, C.; Burke, J.M.; Matasar, M.; Rai, S.; et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2022, 386, 351–363. [Google Scholar] [CrossRef] [PubMed]
  85. Sehn, L.H.; Hertzberg, M.; Opat, S.; Herrera, A.F.; Assouline, S.; Flowers, C.R.; Kim, T.M.; McMillan, A.K.; Özcan, M.; Safar, V.; et al. Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study. Blood 2022, 140 (Suppl. S1), 9464–9467. [Google Scholar] [CrossRef]
  86. Melani, C.; Lakhotia, R.; Pittaluga, S.; Phelan, J.D.; Muppidi, J.R.; Gordon, M.J.; Yang, Y.; Xu, W.; Davies-Hill, T.; Huang, D.W.; et al. Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis. Blood 2024, 144 (Suppl. S1), 1722. [Google Scholar] [CrossRef]
  87. Matasar, M.J.; Haioun, C.; Sancho, J.-M.; Viardot, A.; Hirata, J.; Perretti, T.; Musick, L.; McMillan, A.K. POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood 2021, 138 (Suppl. S1), 3568. [Google Scholar] [CrossRef]
  88. Jerkeman, M.; Leppä, S.; Hamfjord, J.; Brown, P.; Ekberg, S.; Ferreri, A.J.M. S227: Initial Safety Data from The Phase 3 Polar Bear Trial in Elderly or Frail Patients with Diffuse Large Cell Lymphoma, Comparing R-Pola-Mini-Chp and R-Mini-Chop. HemaSphere 2023, 7, e91359ec. [Google Scholar] [CrossRef]
  89. Lynch, R.C.; Poh, C.; Ujjani, C.S.; Warren, E.H.; Smith, S.D.; Shadman, M.; Morris, K.; Rasmussen, H.; Ottemiller, S.; Shelby, M.; et al. Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas. J. Clin. Oncol. 2022, 40, 7546. [Google Scholar] [CrossRef]
  90. Reagan, P. Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL. Report No.: NCT04594798. 2024. Available online: https://clinicaltrials.gov/study/NCT04594798 (accessed on 8 June 2025).
  91. City of Hope Medical Center. A Phase 2 Study of Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Report No.: NCT04665765. 2025. Available online: https://clinicaltrials.gov/study/NCT04665765 (accessed on 8 June 2025).
  92. GWT-TUD GmbH. Open-Label, Prospective Phase III Clinical Study to Compare Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) with Rituximab, Ifosfamide, Carboplatin and Etoposide (R-ICE) Alone as Salvage Therapy in Patients with Primary Refractory or Relapsed Diffuse Large B-Cell Lymphoma (DLBCL). Report No.: NCT04833114. 2025. Available online: https://clinicaltrials.gov/study/NCT04833114 (accessed on 8 June 2025).
  93. Modi, D.; Kim, S.; Pregja, S.; Houde, C.; Reichel, K.A.; Ramchandren, R. A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with Previously Untreated Double and Triple Hit Lymphoma. Blood 2021, 138 (Suppl. S1), 3561. [Google Scholar] [CrossRef]
  94. Wang, W.; Zhang, X.; Li, Q.; Yin, H.; Xiao, X.; Li, J.; Huang, W.; Jing, H.; Zhang, Y. Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R2) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study. Blood 2024, 144 (Suppl. S1), 1728. [Google Scholar] [CrossRef]
  95. Liu, Y. A Prospective, Multicenter, Phase II Study of POLA-R-CHP in the First-Line Treatment of Transformed DLBCL. Report No.: NCT06743945. 2025. Available online: https://clinicaltrials.gov/study/NCT06743945 (accessed on 8 June 2025).
  96. Shi, W. A Prospective, Single-arm, Multicenter Clinical Study of Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Patients with Frail Treatment-naive Non-germinal Center Subtype Diffuse Large B-Cell Lymphoma. Report No.: NCT06530511. 2025. Available online: https://clinicaltrials.gov/study/NCT06530511 (accessed on 8 June 2025).
  97. The First Affiliated Hospital of Soochow University. Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients in Treatment of Newly Diagnosed Untreated Non-GCB DLBCL with Extranodal Involvement. Report No.: NCT06468943. 2024. Available online: https://clinicaltrials.gov/study/NCT06468943 (accessed on 8 June 2025).
  98. Tao, R. Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation: A Prospective, Multicenter, Single-Arm Clinical Study. Report No.: NCT07001540. 2025. Available online: https://clinicaltrials.gov/study/NCT07001540 (accessed on 8 June 2025).
  99. Qian, L. Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. Report No.: NCT06664411. 2024. Available online: https://clinicaltrials.gov/study/NCT06664411 (accessed on 8 June 2025).
  100. Gritti, G.; Marlton, P.; Phillips, T.J.; Arthur, C.; Bannerji, R.; Corradini, P.; Johnston, A.; Seymour, J.F.; Yuen, S.; Hirata, J.; et al. Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study. Blood 2020, 136, 45–47. [Google Scholar] [CrossRef]
  101. Caimi, P.F.; Ai, W.Z.; Alderuccio, J.P.; Ardeshna, K.M.; Hamadani, M.; Hess, B.; Kahl, B.S.; Radford, J.; Solh, M.; Stathis, A.; et al. P1132: Long-Term Responses with Loncastuximab Tesirine: Updated Results from Lotis-2, The Pivotal Phase 2 Study in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. HemaSphere 2023, 7, e402511c. [Google Scholar] [CrossRef]
  102. Carlo-Stella, C.; Zinzani, P.L.L.; Janakiram, M.; Dia, V.; He, X.; Ervin-Haynes, A.; Depaus, J. Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3). Blood 2021, 138, 54. [Google Scholar] [CrossRef]
  103. Kwiatek, M.T.; Carlo-Stella, C.; Urban, A.; Niewiarowski, A.; Wang, L.; Laughlin, M.; Hamadani, M. ABCL-351 LOTIS-5, an Ongoing, Phase 3 Randomized Study of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL. Clin. Lymphoma Myeloma Leuk. 2024, 24, S473–S474. [Google Scholar] [CrossRef]
  104. Alderuccio, J.P. Initial Results from Lotis-7: A Phase 1B Study of Loncastuximab Tesirine Plus Glofitamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Available online: https://library.ehaweb.org/eha/2025/eha2025-congress/4160985/juan.pablo.alderuccio.initial.results.from.lotis-7.a.phase.1b.study.of.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1 (accessed on 8 June 2025).
  105. Istituto Clinico Humanitas. Use of LOncastuximab Tesirine in Patients With RElapsed/Refractory Diffuse LargeB-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) Who Have Progressive Disease After CAR T-Cell Treatment. Report No.: NCT06918912. 2025. Available online: https://clinicaltrials.gov/study/NCT06918912 (accessed on 8 June 2025).
  106. Jacobsen, E.D.; Sharman, J.P.; Oki, Y.; Advani, R.H.; Winter, J.N.; Bello, C.M.; Spitzer, G.; Palanca-Wessels, M.C.; Kennedy, D.A.; Levine, P.; et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015, 125, 1394–1402. [Google Scholar] [CrossRef]
  107. Kim, J.A.; Hahn, U.; Kim, W.-S.; Fleury, I.; Laribi, K.; Burgues, J.M.B.; Bouabdallah, K.; Forward, N.; Bijou, F.; MacDonald, D.; et al. Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study. J. Clin. Oncol. 2024, 42 (Suppl. S17), LBA7005. [Google Scholar] [CrossRef]
  108. Reagan, P. Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients with DLBCL. Report No.: NCT02734771. 2024. Available online: https://clinicaltrials.gov/study/NCT02734771 (accessed on 8 June 2025).
  109. Svoboda, J.; Bair, S.M.; Landsburg, D.J.; Nasta, S.D.; Nagle, S.J.; Barta, S.K.; Khan, N.; Filicko-O’Hara, J.; Gaballa, S.; Strelec, L.; et al. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica 2020, 106, 1705–1713. [Google Scholar] [CrossRef]
  110. Merck Sharp; Dohme LLC. A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants with GCB Subtype of Diffuse Large B-Cell Lymphoma (DLBCL). Report No.: NCT06890884. 2025. Available online: https://clinicaltrials.gov/study/NCT06890884 (accessed on 8 June 2025).
  111. Ozcan, M.; Barca, E.G.; Kim, T.M.; Paszkiewicz-Kozik, E.; Zaucha, J.M.; Hohaus, S.; Ladetto, M.; Patti, C.; Giebel, S.; Robak, T.; et al. Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma. Blood 2024, 144, 578. [Google Scholar] [CrossRef]
  112. Gollard, R.P.T.; Flynn, J.; Reddy, N.; Yusuf, R.Z.; Al-Janadi, A. waveLINE-010: Zilovertamab vedotin plus R-CHP versus R-CHOP in untreated diffuse large B-cell lymphoma. J. Clin. Oncol. 2025, 43, 16. [Google Scholar] [CrossRef]
  113. Armand, P.; Lee, S.T.; Jurczak, W.; Stevens, D.A.; Choquet, S.; Ghesquieres, H.; Norasetthada, L.; Pinto, A.; Saydam, G.; Zhou, H.; et al. WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 2025, 43, 7005. [Google Scholar] [CrossRef]
  114. Norasetthada, L.; Diaz, J.; Lv, F.; Song, Y.; Lee, S.T.; Paszkiewicz-Kozik, E.; Modi, D.; Santoro, A.; Pathiraja, K.; Reddy, N.; et al. Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood 2024, 144, 1738. [Google Scholar] [CrossRef]
  115. Levy, M.Y.; Jagadeesh, D.; Grudeva-Popova, Z.; Trněný, M.; Jurczak, W.; Pylypenko, H.; André, M.; Nasta, S.D.; Rechavi-Robinson, D.; Toffanin, S.; et al. Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin’S B-Cell Lymphomas—A Phase 2 Study. Blood 2021, 138, 526. [Google Scholar] [CrossRef]
  116. Abramson, J.S.; Ku, M.; Hertzberg, M.; Fox, C.P.; Herbaux, C.; Huang, H.; Yoon, D.H.; Kim, W.S.; Zhang, H.; Abdulhaq, H.; et al. Glofitamab Plus Gemcitabine And Oxaliplatin (Glofit-Gemox) In Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl): 2-Year Follow-Up Of Starglo. Hematol. Oncol. 2025, 43, e76_70093. [Google Scholar] [CrossRef]
  117. Melchardt, T. Frontline Phase II Rituximab-Polatuzumab-Glofitmab (R-POLA-GLO) Trial Demonstrates a Manageable Safety Profile and High Response Rates in Elderly and Medical Unfit Patients with Aggressive Lymphoma. Available online: https://library.ehaweb.org/eha/2025/eha2025-congress/4159325/thomas.melchardt.frontline.phase.ii.rituximab-polatuzumab-glofitmab.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31553%2Amarker%3D5843%2Afeatured%3D19595 (accessed on 5 June 2025).
  118. Study Details. Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-Cell Lymphoma Ineligible for R-CHOP. Available online: https://www.clinicaltrials.gov/study/NCT05798156 (accessed on 5 June 2025).
  119. Mohan, M.; Szabo, A.; Cheruvalath, H.; Clennon, A.; Bhatlapenumarthi, V.; Patwari, A.; Balev, M.; Bhutani, D.; Shrestha, A.; Thanendrarajan, S.; et al. Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood Cancer J. 2025, 15, 74. [Google Scholar] [CrossRef]
  120. Crochet, G.; Iacoboni, G.; Couturier, A.; Bachy, E.; Iraola-Truchuelo, J.; Gastinne, T.; Cartron, G.; Fradon, T.; Lesne, B.; Kwon, M.; et al. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood 2024, 144, 334–338. [Google Scholar] [CrossRef]
  121. Brooks, T.R.; Zabor, E.C.; Bedelu, Y.; Yang, X.; Karimi, Y.H.; Nedved, A.N.; Wang, Y.; Dave, N.K.; Landsburg, D.J.; Baron, K.; et al. Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood 2025, in press. [Google Scholar] [CrossRef]
  122. Calabretta, E.; Lu, K.; Zhao, X.; Stewart, C.; Palazzo, M.; Crombie, J.L.; Murakami, M.A.; Herrera, A.F.; Lenz, G.; Morschhauser, F.; et al. The Benefit OF Pola-R-Chp in Dlbclass-Defined Molecular Subsets of Newly Diagnosed Dlbcl in The Polarix Trial. Hematol. Oncol. 2025, 43 (Suppl. S3), eLBA1_70110. [Google Scholar] [CrossRef]
  123. Alderuccio, J.P.; Okada, C.; Crochet, G.; Ayers, E.C.; Hu, M.; Ferrari, S.; Caimi, P.F.; Hamadani, M.; Depaus, J.; Derenzini, E.; et al. Initial Results From Lotis-7: A Phase 1b Study Of Loncastuximab Tesirine Plus Glofitamab In Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (dlbcl). Hematol. Oncol. 2025, 43, e78_70093. [Google Scholar] [CrossRef]
  124. Melani, C.; Lakhotia, R.; Pittaluga, S.; Phelan, J.D.; Huang, D.W.; Wright, G.; Simard, J.; Muppidi, J.; Thomas, C.J.; Ceribelli, M.; et al. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2024, 390, 2143–2155. [Google Scholar] [CrossRef]
  125. Pirosa, M.C.; Stathis, A.; Zucca, E. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma. Hum. Vaccines Immunother. 2024, 20, 2309701. [Google Scholar] [CrossRef]
  126. Düll, J.; Maddocks, K.J.; Gonzalez-Barca, E.; Jurczak, W.; Liberati, A.M.; Obr, A.; Gaidano, G.; Abrisqueta, P.; André, M.; Dreyling, M.H.; et al. Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). J. Clin. Oncol. 2021, 39, 7513. [Google Scholar] [CrossRef]
  127. Larsen, T.S.; Manzke, O.; Leibovitz, D.; Arbushites, M. A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND). Blood 2022, 140 (Suppl. S1), 12077–12078. [Google Scholar] [CrossRef]
  128. Vitolo, U.; Nowakowski, G.S.; Burke, J.M.; Fox, C.P.; Trneny, M.; Chiappella, A.; Waldron-Lynch, M.; Hadar, N.; Pachori, A.; Lenz, G. frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma. J. Clin. Oncol. 2022, 40 (Suppl. S16), TPS7590. [Google Scholar] [CrossRef]
  129. Johnson, P.W.M.; Balasubramanian, S.; Hodkinson, B.; Shreeve, S.M.; Sun, S.; Srinivasan, S.; Steele, A.J.; Vermeulen, J.; Sehn, L.H.; Wilson, W.H. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. Blood Adv. 2023, 7, 2008–2017. [Google Scholar] [CrossRef]
  130. Wilson, W.H.; Wright, G.W.; Huang, D.W.; Hodkinson, B.; Balasubramanian, S.; Fan, Y.; Vermeulen, J.; Shreeve, M.; Staudt, L.M. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell 2021, 39, 1643–1653.e3. [Google Scholar] [CrossRef]
  131. Dyer, M.J.; De Vos, S.; Ruan, J.; Flowers, C.; Maddocks, K.J.; Rule, S.; Hamdy, A.M.; Izumi, R.; Slatter, J.G.; Cheung, J.; et al. Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol. 2018, 36, 7547. [Google Scholar] [CrossRef]
  132. Christofyllakis, K.; Poeschel, V.; Altmann, B.; Maurer, S.; Lesan, V.; Bittenbring, J.; Kos, I.A.; Kaddu-Mulindwa, D.; Abdi, Z.; Fleser, O.; et al. A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1). Blood 2023, 142, 6248. [Google Scholar] [CrossRef]
  133. Sehn, L.H.; Kahl, B.S.; Matasar, M.J.; Lenz, G.; Izutsu, K.; Zhao, W.; Tao, L.; Calvo, R.; Zinzani, P.L. ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol. 2021, 39 (Suppl. S15), TPS7572. [Google Scholar] [CrossRef]
  134. Yin, X.; He, Q.; Liu, D.; Xie, L.; Wang, H.; Chen, C.; Zhao, C.; Shan, N.; Shi, S.; Wei, H.; et al. Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study. Cancer 2025, 131, e35697. [Google Scholar] [CrossRef]
  135. Westin, J.; Davis, R.E.; Feng, L.; Hagemeister, F.; Steiner, R.; Lee, H.J.; Fayad, L.; Nastoupil, L.; Ahmed, S.; Rodriguez, A.; et al. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J. Clin. Oncol. 2023, 41, 745–755. [Google Scholar] [CrossRef]
  136. Westin, J.; E Steiner, R.; Chihara, D.; Ahmed, S.; Jain, P.; Malpica, L.; Iyer, S.P.; Fayad, L.; Nair, R.; Nastoupil, L.J.; et al. Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood 2023, 142 (Suppl. S1), 856. [Google Scholar] [CrossRef]
  137. Morschhauser, F.; Feugier, P.; Flinn, I.W.; Gasiorowski, R.; Greil, R.; Illés, Á.; Johnson, N.A.; Larouche, J.-F.; Lugtenburg, P.J.; Patti, C.; et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood 2021, 137, 600–609. [Google Scholar] [CrossRef]
  138. Vitolo, U.; Novo, M. Bcl-2 inhibition in DLBCL: “the times they are a-changing”? Blood 2021, 137, 577–579. [Google Scholar] [CrossRef] [PubMed]
  139. Vitolo, U.; Trněný, M.; Belada, D.; Burke, J.M.; Carella, A.M.; Chua, N.; Abrisqueta, P.; Demeter, J.; Flinn, I.; Hong, X.; et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 2017, 35, 3529–3537. [Google Scholar] [CrossRef] [PubMed]
  140. Ribrag, V.; Morschhauser, F.; McKay, P.; Salles, G.A.; Batlevi, C.L.; Schmitt, A.; Tilly, H.; Cartron, G.; Thieblemont, C.; Fruchart, C.; et al. Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood 2018, 132 (Suppl. S1), 4196. [Google Scholar] [CrossRef]
  141. Sarkozy, C.; Molina, T.J.; Houot, R.; Dubois, S.; Pica, G.M.; Ruminy, P.; Herbaux, C.; Gastinne, T.; Haioun, C.; Guidez, S.; et al. Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study. Blood 2023, 142, 853. [Google Scholar] [CrossRef]
  142. Kalakonda, N.; Maerevoet, M.; Cavallo, F.; Follows, G.; Goy, A.; Vermaat, J.S.P.; Casasnovas, O.; Hamad, N.; Zijlstra, J.M.; Bakhshi, S.; et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020, 7, e511–e522. [Google Scholar] [CrossRef]
Cancers 17 02517 g001
Figure 1. Therapeutic strategies in B-cell malignancies, illustrating various targeted therapies and immunotherapies. The diagram highlights agents such as BCL2 inhibitors (e.g., venetoclax), BTK inhibitors, antibody–drug conjugates (ADCs) targeting specific tumor antigens (e.g., CD79b, CD19, CD30, ROR1), immune checkpoint inhibitors that block PD-1 or PD-L1 pathways, CD19 monoclonal antibodies, and bispecific antibodies that bridge tumor cells (via CD19/CD20) with T cells (via CD3) to induce anti-tumor responses (Pola—polatuzumab vedotin; Lonca—loncastuximab tesirine; Brentux—brentuximab vedotin; Zilo—zilovertamab vedotin).
Figure 1. Therapeutic strategies in B-cell malignancies, illustrating various targeted therapies and immunotherapies. The diagram highlights agents such as BCL2 inhibitors (e.g., venetoclax), BTK inhibitors, antibody–drug conjugates (ADCs) targeting specific tumor antigens (e.g., CD79b, CD19, CD30, ROR1), immune checkpoint inhibitors that block PD-1 or PD-L1 pathways, CD19 monoclonal antibodies, and bispecific antibodies that bridge tumor cells (via CD19/CD20) with T cells (via CD3) to induce anti-tumor responses (Pola—polatuzumab vedotin; Lonca—loncastuximab tesirine; Brentux—brentuximab vedotin; Zilo—zilovertamab vedotin).
Cancers 17 02517 g001
Table 1. List of immunotherapies and targeted therapy clinical trials in DLBCL.
Table 1. List of immunotherapies and targeted therapy clinical trials in DLBCL.
Trial NameDrug(s)PopulationPhaseOR (CR)
Epcoritamab
EPCORE NHL-1; GCT3013-01 [11] Subcutaneous Epcoritamab CD20+ mature B-cell neoplasm (diffuse large B-cell lymphoma (DLBCL) or other aggressive non-Hodgkin lymphomas, including primary mediastinal LBCL, high-grade B-cell lymphoma, or follicular lymphoma grade 3B)I/II63 (39)
EPCORE NHL-2 (NCT04663347)
[12,13,14,15,16,17]		Epcoritamab plus GemOx [15]ASCT-ineligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)IB/II91 (59)
Epcoritamab + R-DHAX/C [13]Transplant-eligible patients (pts) with high-risk re
lapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)		IB/II76 (69)
Epcoritamab SC + R-mini-CHOP [16]1L DLBCL who were not considered candidates for full-dose R-CHOPIB/II89 (82)
Epcoritamab + RICE [17]R/R DLBCL eligible for ASCT IB/II87 (65)
EPCORE NHL-5 (NCT05283720)Epcoritamab Plus Lenalidomide [18]Relapsed or refractory (R/R) DLBCLIB/II67 (51)
Epcoritamab + pola-R-CHP [19]Newly diagnosed CD20+ DLBCLIB/II100
(97)
EPCORE
DLBCL-3 [20,21]		Epcoritamab monotherapyElderly pts with 1L CD20+ LBCL who were ineligible for anthracycline-based tx due to age ≥ 80 y or age ≥ 75 y with underlying comorbidities II78 (70)
EPCORE DLBCL-1
NCT04628494
[22]		Epcoritamab vs. investigator’s choice of chemotherapyRelapsed, refractory DLBCL who have failed or are ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT)IIIOngoing
Glotifamab
STARGLO
(NCT0353283) [23]		Glofitamab plus gemcitabine–oxaliplatin (Glofit-GemOx) versus rituximab (R)-GemOx Transplant-ineligible patients (aged ≥ 18 years) with histologically confirmed relapsed or refractory diffuse large B-cell lymphoma III25.5 vs.12.9
NCT03075696 [24,25,26]Glofitamab + obinutuzumabRelapsed or refractory DLBCL who had received at least two lines of therapy previouslyII52 (39)
LYSA NCT04703686 [27]GlofitamabRefractory or relapsed diffuse large B-cell lymphoma after failing CAR-T cell therapyII76 (45)
NCT03533283 [28]Glofitamab + Polatuzumab VedotinHeavily pretreated relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including high-grade B-cell lymphoma (HGBCL)IB/II80 (62)
NCT03467373 [29]Glofitamab + Pola-R-CHPPreviously untreated diffuse large B-cell lymphoma (DLBCL)IB100 (76)
SKYGLO NCT06047080 [30]Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) versus Pola-R-CHPPreviously untreated CD20-positive LBCLIIIOngoing
NCT04980222 [31]Glofitamab Plus R-CHOPPreviously untreated (1L) large B-cell lymphoma (LBCL) defined as high risk by circulating tumor DNA (ctDNA) dynamicsII93 (80)
NCT05364424 [32]Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and EtoposideRelapsed or refractory diffuse large B-cell lymphoma, eligible for stem cell transplant or chimeric antigen receptor T-cell therapyIB78 (68)
NCT04077723
[33]		Englumafusp Alfa + GlofitamabRelapsed or refractory B-NHL after at least one prior treatmentIB(aNHL/iNHL) ORR 67.5%/91.7%
CR 56.6%/79.2%
COALITION NCT04914741
[34,35]		Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHPYounger patients with high-burden, high-risk large B-cell lymphomaIB/II100 (92)
NCT05798156
[34,35]		R-Pola-GloElderly/frail and medically unfit pts with aggressive lymphomaII90 (82)
Odronextamab
ELM-1 study NCT02290951 [36]OdronextamabRelapsed/Refractory (R/R) B-cell non-Hodgkin lymphoma after ≥2 lines of therapy—post CAR-T DLBCL cohortI48 (31)
ELM-2 study NCT03888105 [37]OdronextamabRelapsed/Refractory (R/R) B-cell non-Hodgkin lymphoma after ≥2 lines of therapy—DLBCL cohortII52 (31.5)
OLYMPIA-3 (NCT06091865)
[38]		Odronextamab plus CHOP vs. rituximab plus CHOPPreviously untreated diffuse large B-cell lymphomaIIIOngoing
OLYMPIA-4 (EudraCT 2022-502783-21-00) [39]Odronextamab versus Standard of care Previously treated aggressive B-NHLIIIOngoing
Mosunetuzumab
NCT02500407 [40]MosunetuzumabRelapsed/refractory diffuse large B-cell lymphomaI/II42 (24)
NCT03677141
[41] 		Mosunetuzumab with CHOPPreviously untreated DLBCLII87.5 (85)
NCT03677154 [42]MosunetuzumabElderly/unfit patients with 1L DLBCLI/II67.7 (42)
NCT03671018
[43,44]		Mosunetuzumab + polatuzumab vedotin
[43]		Relapsed/refractory aggressive large B-cell lymphoma (LBCL)Ib/II59.2 (45.9)
M (SC
administration)-Pola vs. rituximab (R)-Pola
[44]		IIOR 78 vs. 50; CR 58 vs. 35
SUNMO (NCT05171647)
[45,46]		Mosun + Pola (M-Pola) vs. IV rituximab + gemcitabine and oxaliplatin (R-GemOx)CD20-positive R/R aNHL, ≥1 prior systemic therapy (if only one prior line of therapy, pts must be ineligible for ASCT)III70.3 (51.4)
NCT05672251
[47]		Loncastuximab tesirine (Lonca) + MosunetuzumabR/RL DLBCL after ≥2 prior lines of therapyIIOngoing
NCT06015880
[48]		Mosunetuzumab, Pola, LenalidomideRelapsed/refractory diffuse large B-cell lymphomaIOngoing
Plamotamab
NCT02924402
[49,50]		Plamotamab IV
[49]		Relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL)I47 (26)
Plamotamab SC
[50]		Heavily pretreated R/R NHL patients who had prior CAR-T cell therapyI53 (24)
XmAb13676-03
NCT05328102
[51]		Plamotamab + TAFA + LEN versus TAFA + LENDLBCL who have relapsed or are refractory to ≥1 prior line of therapy and are ineligible for or refuse ASCTIIOngoing
Blinatumomab
NCT01741792
[52]		BlinatumomabRelapsed/refractory DLBCLII43 (19)
NCT03340766
[53]		Blinatumomab + Pembrolizumab Relapsed/refractory DLBCLIB30, Terminated due to lack of efficacy
NCT03072771
[54]		Blinatumomab consolidation after auto-SCTRelapsed diffuse large B-cell lymphoma (DLBCL), who undergo autologous stem cell transplantI1 yr—50% CR
NCT03023878
[55]		Blinatumomab following an induction with R- chemotherapyAdults with newly diagnosed, high-risk DLBCLII-
NCT02568553
[56]		Lenalidomide + BlinatumomabRelapsed or refractory non-Hodgkin’s lymphoma (NHL)IOngoing
Atezolizumab
HOVON 151 trial
NCT03463057
[57]		AtezolizumabDLBCL patients with an international prognostic index (IPI) score of ≥3 and CMR after R-CHOPII2-year: DFS 87.9% OS 96.3%
NCT02220842Atezolizumab + Obinutuzumab
[58]		Relapsed or refractory DLBCL or FLIb17 (4)
Atezolizumab + Tazemetostat
[59]		Relapsed or refractory DLBCLIb16 (7)
NCT02596971
[60]		Atezolizumab + RCHOPPreviously untreated advanced DLBCLIb/II87.5 (77.5)
NCT03321643
[61]		Atezolizumab + rituximab + GemOx (R-GemOx + Atezo)R/R transformed DLBCL, including Richter transformationI/II59 (33)
NCT04082897
MOLTO
[62,63]		Atezolizumab + venetoclax + obinutuzumabRichter transformation diffuse large B-cell lymphomaII67.9 (28.6)
NCT03276468
LYSA
[64,65]		Atezolizumab + venetoclax + obinutuzumabRelapsed/refractory B non-Hodgkin lymphomaII23.6 (18)
Durvalumab
NCT03003520
[66]		Durvalumab in combination with R-CHOP or R2-CHOPPreviously untreated, high-risk DLBCLIIOngoing; 54% Arm A; 67% Arm B
NCT03685344
[67]		Loncastuximab Tesirine + DurvalumabR/R DLBCL, MCL, or FLI/IIOngoing
Pembrolizumab
KEYNOTE-170
NCT02576990
[68]		PembrolizumabRelapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) whose disease progressed after or who were ineligible for autologous stem cell transplantationII41 (20)
NCT02332980
[69]		Pembrolizumab Alone or With Idelalisib or IbrutinibCLL patients with biopsy-proven Richter transformation to diffuse large B-cell lymphomaII23 (7.7)
PORTIA trial
NCT03630159
[70]		Tisagenlecleucel + pembrolizumabRelapsed or refractory DLBCLIb50 (33.3)
KEYNOTE-013 study NCT01953692
[71]		pembrolizumab (cohort 4) or pembrolizumab plus lenalidomide (cohort5)Relapsed or refractory NHL who were ineligible for or failed
hematopoietic cell transplantation (HCT)		Ib22 (12)/39 (22)
NCT02684617 KEYNOTE-155
[72]		Pembrolizumab + DinaciclibRelapsed or refractory DLBCLIb21 (10.5)
NCT03150329
[73]		Pembrolizumab + vorinostatRelapsed/refractory B-cell NHL—DLBCL cohortI55 (45)
KEYNOTE145
NCT02362035
[74]		Acalabrutinib + pembrolizumabRelapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)I/II26 (7)
SPiReL trial NCT03349450
[75]		Pembrolizumab, low-dose cyclophosphamide, +DPX-SurvivacRelapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)II63 (27)
NCT02541565
[76]		Pembrolizumab with R-CHOPUntreated DLBCL or grade 3b follicular lymphoma 90 (77)
NCT02650999
[77]		PembrolizumabRelapsed/refractory B-cell lymphomas after CD19-directed CAR T cellsIa/II25
Alexander
NCT03287817
[78]		Pembrolizumab + AUTO3, a CAR T targeting CD19/22r/r DLBCL (NOS) or transformed (tDLBCL)I64 (55)
Nivolumab
CheckMate 139
NCT02038933
[79]		NivolumabRelapsed/refractory DLBCL who were ineligible for autologous hematopoietic cell transplantation (auto-HCT) or who had experienced failure with auto-HCTIIauto-HCT–failed: 10 (3)
auto-HCT–ineligible: 3 (0)
NCT03259529
[80]		Nivolumab, bendamustine, gemcitabine + rituximab (BeGeRN)Relapsed or refractory B-cell non-Hodgkin lymphomaI/II45.5 (18)
HOVON-152
NCT03620578
[81]		DA-EPOCH-R Induction and Nivolumab Consolidation TreatmentNewly diagnosed High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements II61% CMR
CheckMate 436
NCT02581631
[82]		Nivolumab + Brentuximab Vedotin Relapsed/refractory primary mediastinal large B-cell lymphomaII70 (43)
Polatuzumab Vedotin
POLARIX
NCT03274492
[83,84]		Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, Prednisone (Pola-R-CHP) vs. R-CHOPPreviously untreated intermediate-risk or high-risk DLBCLIII2 year PFS: 76.7% (Pola-R-CHP) vs. 70.2% (R-CHOP)
NCT02257567
[85]		Pola + bendamustine + rituximab (Pola + BR) vs. BR aloneRelapsed/refractory diffuse large B-cell lymphomaIb/IIBoR:62.5% vs. 25.0%
BCR:52.5% vs. 22.5%
PFS:9.2 vs. 3.7 mo
NCT04739813
[86]		Polatuzumab, Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide (ViPOR-P)Relapsed/refractory diffuse large B-cell lymphomaI/II75 (50)
POLARGO
NCT04182204
[87]		Pola-R-GemOx vs. R-GemOxRelapsed/refractory diffuse large B-cell lymphomaIII52.7 (40.3)
POLAR BEAR
NCT04332822
[88]		Pola-R-miniCHP vs.
R-miniCHOP		Newly diagnosed DLBCL, >80 years, or 75–80 years and frailIIIOngoing
NCT04231877
PERCH
[89]		Pola, etoposide, cyclophosphamide, doxorubicin, rituximab (Pola-DA-EPCH-R)Aggressive large B-cell lymphomasI93 (71)
NCT04594798
[90]		Pola, Rituximab and Dose Attenuated CHPNewly diagnosed DLBCL patients 75 years and older IIOngoing
NCT04665765
[91]		Pola, rituximab, ifosfamide, carboplatin, etoposide (PolaR-ICE)First salvage therapy for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)IIOngoing
NCT04833114
[92]		Pola, rituximab, ifosfamide, carboplatin, etoposide (Pola-R-ICE) vs. rituximab, ifosfamide, carboplatin and etoposide (R-ICE)Salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)IIIOngoing
NCT04479267
[93]		Pola, Rituximab, Cyclophosphamide, Doxorubicin, PrednisonePatients aged > 18 years with previously untreated double- or triple-hit lymphomaIIOngoing
NCT06176729
[94]		Pola, Rituximab Lenalidomide (Pola-R2)Newly diagnosed DLBCL patients aged over 70 years old and unfit or frailIIEOT CRR 100%
NCT06743945
[95]		POLA-R-CHPPatients with transformed DLBCLIIOngoing
NCT06530511
[96]		Polatuzumab, Rituximab, Orelabrutinib (PRO)Elderly patients with frail, treatment-naïve, non-germinal center subtype diffuse large B-cell lymphomaIIOngoing
NCT06468943
[97]		Pola, Zanubrutinib, R-CHPNewly diagnosed untreated non-GCB DLBCL patients with extranodal involvementIIOngoing
NCT06015880
[48]		Mosunetuzumab, Pola, LenalidomideRelapsed/refractory diffuse large B-cell lymphomaIOngoing
NCT07001540
[98]		Pola-R-GemOxSalvage therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous transplantationIIOngoing
NCT06664411
[99]		Pola, Zanubrutinib, Rituximab, Lenalidomide Prednisone Pola-ZR2PPreviously untreated DLBCLIIOngoing
NCT02611323
[100]		Pola, Venetoclax, Rituximab
Pola-Ven-R		Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)Ib/II65 (31)
Loncastuximab tesirine
LOTIS 2
NCT03589469
[101]		LoncastuximabRelapsed/refractory diffuse large B-cell lymphomaII48 (25)
LOTIS-3 NCT03684694
[102]		Loncastuximab + ibrutinibRelapsed/refractory diffuse large B-cell lymphomaI/II57 (34)
LOTIS-5 NCT04384484
[103]		Lonca-R vs. R + gemcitabine + oxaliplatin (R-GemOx)Relapsed/refractory diffuse large B-cell lymphomaIIIOngoing
Prelim: 80 (50)
LOTIS-7 NCT04970901
[104]		Lonca + Pola (arm C), glofitamab (arm E), or mosunetuzumab (arm F)Relapsed/refractory diffuse large B-cell lymphomaIbLonca + Glofit 95 (90.9)
LORELY
NCT06918912
[105]		LoncastuximabRelapsed/refractory diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) following CAR-T therapy failureIIOngoing
Brentuximab vedotin
NCT01421667
[106]		BrentuximabRelapsed/refractory diffuse large B-cell lymphomaII44 (17)
ECHELON-3
NCT04404283
[107]		Brentuximab vedotin, lenalidomide, rituximab vs. R2Relapsed/refractory diffuse large B-cell lymphomaIII70.9 (45.6)
NCT02734771
[108]		Brentuximab Vedotin, Rituximab, Dose Attenuated CHP Elderly patients with newly diagnosed DLBCLIIOngoing
NCT01994850
[109]		Brentuximab vedotin (BV) rituximab, cyclophosphamide, doxorubicin, prednisone (R-CHP)CD30-positive (+) B-cell lymphomasI/II100 (86)
Zilovertamab Vedotin
waveLINE-011
NCT06890884
[110]		Zilovertamab Vedotin +R-CHP vs. Pola + R-CHPTreatment-naïve DLBCL, GCB subtypeIIOngoing
waveLINE-007 NCT05406401
[111]		Zilovertamab vedotin + R-CHPPreviously untreated DLBCLII100 (100)
waveLINE-010 NCT06717347
[112]		Zilovertamab vedotin + R-CHP vs. R-CHOPPreviously untreated DLBCLIIIOngoing
waveLINE-003 NCT05139017
[113]		Zilovertamab vedotin, rituximab, gemcitabine-oxaliplatin (R-GemOx)Relapsed/refractory DLBCLII/III56
waveLINE-004
NCT05144841
[114]		Zilovertamab vedotinRelapsed/refractory DLBCLII29 (13)
Naratuximab Emtansine
NCT02564744
[115]		Naratuximab Emtansine, rituximabRelapsed and/or refractory (R/R) B-NHLII44 (31)
Abbreviations: R/R = relapsed/refractory; DLBCL = diffuse large B-cell lymphoma; ASCT = autologous stem cell transplant; CR = complete response; ORR = overall response rate; PFS = progression-free survival; OS = overall survival; NE = not estimable.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chaudhari, J.; Shah, N.N. Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma. Cancers 2025, 17, 2517. https://doi.org/10.3390/cancers17152517

AMA Style

Chaudhari J, Shah NN. Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma. Cancers. 2025; 17(15):2517. https://doi.org/10.3390/cancers17152517

Chicago/Turabian Style

Chaudhari, Jahnavi, and Nikesh N. Shah. 2025. "Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma" Cancers 17, no. 15: 2517. https://doi.org/10.3390/cancers17152517

APA Style

Chaudhari, J., & Shah, N. N. (2025). Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma. Cancers, 17(15), 2517. https://doi.org/10.3390/cancers17152517

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop